{"title":"Bestsellers","description":"\u003cp data-start=\"273\" data-end=\"605\"\u003eExplore the RCpeptides Bestsellers Collection – our most popular and trusted research peptides chosen by scientists and researchers worldwide. Each peptide is produced to the highest standards of purity and consistency, making them the go-to choice for reliable research results.\u003c\/p\u003e\n\u003cp data-start=\"607\" data-end=\"944\"\u003eWhether you’re looking to buy peptides online for ongoing projects or starting new research, our bestselling peptides represent the perfect balance of quality, trust, and customer satisfaction. At RCpeptides, we are committed to delivering premium-grade peptides with full transparency, fast shipping, and professional support.\u003c\/p\u003e","products":[{"product_id":"slu-pp-332-5mg-vial","title":"SLU-pp-332 10mg vial","description":"\u003cp style=\"text-align: center;\"\u003e\u003cstrong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eN\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eOT FOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"44\" data-end=\"757\"\u003e\u003cstrong\u003eSLU-PP-332 \u003c\/strong\u003eis a small-molecule \u003cstrong data-start=\"108\" data-end=\"165\"\u003epan–estrogen-related receptor (ERR) agonist\/modulator\u003c\/strong\u003e reported by researchers at Saint Louis University as a pharmacologic \u003cstrong data-start=\"235\" data-end=\"258\"\u003e“exercise mimetic.”\u003c\/strong\u003e By activating \u003cstrong data-start=\"273\" data-end=\"299\"\u003eERRα\/β\/γ (NR3B family)\u003c\/strong\u003e—transcription factors that partner with \u003cstrong data-start=\"340\" data-end=\"350\"\u003ePGC-1α\u003c\/strong\u003e—SLU-PP-332 up-regulates programs for \u003cstrong data-start=\"388\" data-end=\"484\"\u003emitochondrial biogenesis, fatty-acid oxidation (FAO), and oxidative phosphorylation (OXPHOS)\u003c\/strong\u003e. In diet-induced-obese mice, the compound has been described to \u003cstrong data-start=\"549\" data-end=\"591\"\u003eincrease whole-body energy expenditure\u003c\/strong\u003e, \u003cstrong data-start=\"593\" data-end=\"614\"\u003elimit weight gain\u003c\/strong\u003e, and \u003cstrong data-start=\"620\" data-end=\"649\"\u003eimprove glucose tolerance\u003c\/strong\u003e without requiring additional exercise. It is \u003cstrong data-start=\"695\" data-end=\"719\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; available data are \u003cstrong data-start=\"740\" data-end=\"756\"\u003epre-clinical\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"759\" data-end=\"762\"\u003e\n\u003ch3 data-start=\"764\" data-end=\"825\"\u003eAdditional Benefits of SLU-PP-332 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"827\" data-end=\"3030\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"827\" data-end=\"855\"\u003e\n\u003ctr data-start=\"827\" data-end=\"855\"\u003e\n\u003cth data-start=\"827\" data-end=\"837\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"837\" data-end=\"855\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"866\" data-end=\"3030\"\u003e\n\u003ctr data-start=\"866\" data-end=\"1144\"\u003e\n\u003ctd data-start=\"866\" data-end=\"910\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"868\" data-end=\"909\"\u003e1 Energy-expenditure \u0026amp; weight control\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"910\" data-end=\"1144\" data-col-size=\"xl\"\u003eIn obese mice, SLU-PP-332 \u003cstrong data-start=\"938\" data-end=\"955\"\u003eraises VO₂\/EE\u003c\/strong\u003e and \u003cstrong data-start=\"960\" data-end=\"981\"\u003ereduces adiposity\u003c\/strong\u003e largely \u003cstrong data-start=\"990\" data-end=\"1020\"\u003eindependent of food intake\u003c\/strong\u003e, aligning with ERR-driven oxidative remodeling. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint (SLU group); Cell Metabolism (ERR biology)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1145\" data-end=\"1399\"\u003e\n\u003ctd data-start=\"1145\" data-end=\"1193\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1147\" data-end=\"1192\"\u003e2 Glycaemic control \u0026amp; insulin sensitivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1193\" data-end=\"1399\" data-col-size=\"xl\"\u003eImproves \u003cstrong data-start=\"1204\" data-end=\"1225\"\u003eglucose tolerance\u003c\/strong\u003e and \u003cstrong data-start=\"1230\" data-end=\"1251\"\u003einsulin tolerance\u003c\/strong\u003e with increased skeletal-muscle \u003cstrong data-start=\"1283\" data-end=\"1290\"\u003eAkt\u003c\/strong\u003e signalling and reduced hepatic lipogenesis. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Diabetes (mechanistic context)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1400\" data-end=\"1671\"\u003e\n\u003ctd data-start=\"1400\" data-end=\"1436\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1402\" data-end=\"1435\"\u003e3 Endurance\/fitness phenotype\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1436\" data-end=\"1671\" data-col-size=\"xl\"\u003eIn treadmill assays, treated mice exhibit \u003cstrong data-start=\"1480\" data-end=\"1509\"\u003elonger time-to-exhaustion\u003c\/strong\u003e and greater \u003cstrong data-start=\"1522\" data-end=\"1542\"\u003erunning distance\u003c\/strong\u003e, consistent with \u003cstrong data-start=\"1560\" data-end=\"1574\"\u003ePGC-1α\/ERR\u003c\/strong\u003e endurance programs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Journal of Physiology (PGC-1α\/ERR context)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1672\" data-end=\"1896\"\u003e\n\u003ctd data-start=\"1672\" data-end=\"1698\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1674\" data-end=\"1697\"\u003e4 Hepatic steatosis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1698\" data-end=\"1896\" data-col-size=\"xl\"\u003eDown-regulates \u003cstrong data-start=\"1715\" data-end=\"1731\"\u003eSREBP1c\/FASN\u003c\/strong\u003e and up-regulates \u003cstrong data-start=\"1749\" data-end=\"1772\"\u003eCPT1A\/PPARα targets\u003c\/strong\u003e, reducing \u003cstrong data-start=\"1783\" data-end=\"1806\"\u003eliver triglycerides\u003c\/strong\u003e in NAFLD models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Hepatology (ERR in hepatic lipid flux)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1897\" data-end=\"2150\"\u003e\n\u003ctd data-start=\"1897\" data-end=\"1930\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1899\" data-end=\"1929\"\u003e5 Mitochondrial biogenesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1930\" data-end=\"2150\" data-col-size=\"xl\"\u003eIncreases \u003cstrong data-start=\"1942\" data-end=\"1963\"\u003emtDNA copy number\u003c\/strong\u003e, \u003cstrong data-start=\"1965\" data-end=\"1994\"\u003eOXPHOS complex expression\u003c\/strong\u003e, and \u003cstrong data-start=\"2000\" data-end=\"2010\"\u003ePGC-1α\u003c\/strong\u003e target genes in muscle and brown\/brite fat. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Nature Reviews Molecular Cell Biology (mitochondrial control)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2151\" data-end=\"2383\"\u003e\n\u003ctd data-start=\"2151\" data-end=\"2189\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2153\" data-end=\"2188\"\u003e6 WAT browning \u0026amp; BAT activation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2189\" data-end=\"2383\" data-col-size=\"xl\"\u003eInduces \u003cstrong data-start=\"2199\" data-end=\"2207\"\u003eUCP1\u003c\/strong\u003e, \u003cstrong data-start=\"2209\" data-end=\"2217\"\u003eDIO2\u003c\/strong\u003e, and thermogenic genes with \u003cstrong data-start=\"2246\" data-end=\"2272\"\u003esmaller adipocyte size\u003c\/strong\u003e, pointing to beige fat recruitment. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Molecular Metabolism (ERR thermogenesis)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2384\" data-end=\"2603\"\u003e\n\u003ctd data-start=\"2384\" data-end=\"2416\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2386\" data-end=\"2415\"\u003e7 Anti-inflammatory shift\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2416\" data-end=\"2603\" data-col-size=\"xl\"\u003eReduces \u003cstrong data-start=\"2426\" data-end=\"2440\"\u003eTNF-α\/IL-6\u003c\/strong\u003e and \u003cstrong data-start=\"2445\" data-end=\"2470\"\u003ecrown-like structures\u003c\/strong\u003e in adipose tissue, aligning with improved insulin signalling. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Cardiovascular Diabetology (context)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2604\" data-end=\"2815\"\u003e\n\u003ctd data-start=\"2604\" data-end=\"2632\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2606\" data-end=\"2631\"\u003e8 Exercise additivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2632\" data-end=\"2815\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2634\" data-end=\"2655\"\u003eAdditive benefits\u003c\/strong\u003e when layered on voluntary running—higher oxidative gene expression and endurance than either alone. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Exercise-genomics reviews\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2816\" data-end=\"3030\"\u003e\n\u003ctd data-start=\"2816\" data-end=\"2857\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2818\" data-end=\"2856\"\u003e9 Lipids \u0026amp; cardiometabolic profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2857\" data-end=\"3030\" data-col-size=\"xl\"\u003eLowers \u003cstrong data-start=\"2866\" data-end=\"2882\"\u003eplasma TG\/TC\u003c\/strong\u003e and improves \u003cstrong data-start=\"2896\" data-end=\"2906\"\u003eHDL:TG\u003c\/strong\u003e ratios in rodents; human relevance pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;bioRxiv preprint; Journal of Lipid Research (ERR lipid biology)\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3032\" data-end=\"3035\"\u003e\n\u003ch2 data-start=\"3037\" data-end=\"3072\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3074\" data-end=\"3107\"\u003e2.1 Target Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3108\" data-end=\"3573\"\u003e\n\u003cli data-start=\"3108\" data-end=\"3237\"\u003e\n\u003cp data-start=\"3110\" data-end=\"3237\"\u003e\u003cstrong data-start=\"3110\" data-end=\"3130\"\u003ePrimary targets:\u003c\/strong\u003e \u003cstrong data-start=\"3131\" data-end=\"3143\"\u003eERRα\/β\/γ\u003c\/strong\u003e nuclear receptors (constitutive transcription factors) that are \u003cstrong data-start=\"3208\" data-end=\"3234\"\u003eco-activated by PGC-1α\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3238\" data-end=\"3446\"\u003e\n\u003cp data-start=\"3240\" data-end=\"3446\"\u003e\u003cstrong data-start=\"3240\" data-end=\"3262\"\u003eSLU-PP-332 action:\u003c\/strong\u003e \u003cstrong data-start=\"3263\" data-end=\"3317\"\u003eStabilizes\/activates ERR transcriptional complexes\u003c\/strong\u003e, increasing transcription of \u003cstrong data-start=\"3347\" data-end=\"3375\"\u003eFAO\/OXPHOS\/mitochondrial\u003c\/strong\u003e genes across oxidative tissues (skeletal muscle, heart, BAT, liver).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3447\" data-end=\"3573\"\u003e\n\u003cp data-start=\"3449\" data-end=\"3573\"\u003e\u003cstrong data-start=\"3449\" data-end=\"3473\"\u003ePhysiologic analogy:\u003c\/strong\u003e Mimics transcriptional changes seen after \u003cstrong data-start=\"3516\" data-end=\"3538\"\u003eendurance exercise\u003c\/strong\u003e or \u003cstrong data-start=\"3542\" data-end=\"3572\"\u003ecold-induced thermogenesis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3575\" data-end=\"3602\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3604\" data-end=\"4189\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3604\" data-end=\"3646\"\u003e\n\u003ctr data-start=\"3604\" data-end=\"3646\"\u003e\n\u003cth data-start=\"3604\" data-end=\"3614\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3614\" data-end=\"3635\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3635\" data-end=\"3646\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3661\" data-end=\"4189\"\u003e\n\u003ctr data-start=\"3661\" data-end=\"3779\"\u003e\n\u003ctd data-start=\"3661\" data-end=\"3699\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3663\" data-end=\"3698\"\u003ePGC-1α–ERR transcriptional axis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3699\" data-end=\"3757\" data-col-size=\"md\"\u003e↑ Mitochondrial biogenesis (NRF1\/TFAM), ↑ OXPHOS, ↑ FAO\u003c\/td\u003e\n\u003ctd data-start=\"3757\" data-end=\"3779\" data-col-size=\"sm\"\u003eMuscle, BAT, liver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3780\" data-end=\"3885\"\u003e\n\u003ctd data-start=\"3780\" data-end=\"3807\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3782\" data-end=\"3806\"\u003ePPAR\/AMPK cross-talk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3807\" data-end=\"3868\" data-col-size=\"md\"\u003e↑ CPT1A\/ACADs, ↑ lipid oxidation; partial AMPK convergence\u003c\/td\u003e\n\u003ctd data-start=\"3868\" data-end=\"3885\" data-col-size=\"sm\"\u003eLiver, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3886\" data-end=\"4001\"\u003e\n\u003ctd data-start=\"3886\" data-end=\"3912\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3888\" data-end=\"3911\"\u003eMyofiber remodeling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3912\" data-end=\"3982\" data-col-size=\"md\"\u003eShift toward oxidative type I\/IIA fibers; ↑ capillary density genes\u003c\/td\u003e\n\u003ctd data-start=\"3982\" data-end=\"4001\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4002\" data-end=\"4089\"\u003e\n\u003ctd data-start=\"4002\" data-end=\"4028\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4004\" data-end=\"4027\"\u003eThermogenic program\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4028\" data-end=\"4072\" data-col-size=\"md\"\u003e↑ UCP1\/UCP3, ↑ DIO2, ↑ β-oxidation → ↑ EE\u003c\/td\u003e\n\u003ctd data-start=\"4072\" data-end=\"4089\" data-col-size=\"sm\"\u003eBAT\/brite WAT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4090\" data-end=\"4189\"\u003e\n\u003ctd data-start=\"4090\" data-end=\"4113\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4092\" data-end=\"4112\"\u003eInflammation\/ECM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4113\" data-end=\"4172\" data-col-size=\"md\"\u003e↓ Pro-inflammatory cytokines, ↓ adipose fibrosis markers\u003c\/td\u003e\n\u003ctd data-start=\"4172\" data-end=\"4189\" data-col-size=\"sm\"\u003eAdipose\/liver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"4191\" data-end=\"4194\"\u003e\n\u003ch2 data-start=\"4196\" data-end=\"4218\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"4220\" data-end=\"4728\"\u003e\n\u003cli data-start=\"4220\" data-end=\"4310\"\u003e\n\u003cp data-start=\"4222\" data-end=\"4310\"\u003e\u003cstrong data-start=\"4222\" data-end=\"4237\"\u003eRoute\/form:\u003c\/strong\u003e \u003cstrong data-start=\"4238\" data-end=\"4256\"\u003eSmall-molecule\u003c\/strong\u003e administered to rodents; detailed human PK unknown.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4311\" data-end=\"4457\"\u003e\n\u003cp data-start=\"4313\" data-end=\"4457\"\u003e\u003cstrong data-start=\"4313\" data-end=\"4326\"\u003eExposure:\u003c\/strong\u003e Pre-clinical reports indicate \u003cstrong data-start=\"4357\" data-end=\"4378\"\u003esystemic exposure\u003c\/strong\u003e compatible with once-daily paradigms in mice; \u003cstrong data-start=\"4425\" data-end=\"4446\"\u003ebrain penetration\u003c\/strong\u003e unclear.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4458\" data-end=\"4597\"\u003e\n\u003cp data-start=\"4460\" data-end=\"4597\"\u003e\u003cstrong data-start=\"4460\" data-end=\"4484\"\u003eHalf-life\/clearance:\u003c\/strong\u003e Not publicly established; presumed \u003cstrong data-start=\"4520\" data-end=\"4537\"\u003ehepatic\/renal\u003c\/strong\u003e clearance typical of lipophilic transcription-modulators.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4598\" data-end=\"4728\"\u003e\n\u003cp data-start=\"4600\" data-end=\"4728\"\u003e\u003cstrong data-start=\"4600\" data-end=\"4627\"\u003eDrug–drug interactions:\u003c\/strong\u003e No clinical data; ERRs \u003cstrong data-start=\"4651\" data-end=\"4681\"\u003eregulate metabolic enzymes\u003c\/strong\u003e, so \u003cstrong data-start=\"4686\" data-end=\"4698\"\u003eindirect\u003c\/strong\u003e interactions are conceivable.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4730\" data-end=\"4733\"\u003e\n\u003ch2 data-start=\"4735\" data-end=\"4780\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4782\" data-end=\"4820\"\u003e4.1 Obesity \u0026amp; Metabolic Syndrome\u003c\/h3\u003e\n\u003cp data-start=\"4821\" data-end=\"5012\"\u003eDiet-induced-obese mice treated with SLU-PP-332 display \u003cstrong data-start=\"4877\" data-end=\"4897\"\u003eless weight gain\u003c\/strong\u003e, \u003cstrong data-start=\"4899\" data-end=\"4916\"\u003ehigher VO₂\/EE\u003c\/strong\u003e, \u003cstrong data-start=\"4918\" data-end=\"4946\"\u003ebetter glucose tolerance\u003c\/strong\u003e, and \u003cstrong data-start=\"4952\" data-end=\"4974\"\u003esmaller adipocytes\u003c\/strong\u003e, with \u003cstrong data-start=\"4981\" data-end=\"4993\"\u003ebrowning\u003c\/strong\u003e signatures in WAT.\u003c\/p\u003e\n\u003ch3 data-start=\"5014\" data-end=\"5029\"\u003e4.2 NAFLD\u003c\/h3\u003e\n\u003cp data-start=\"5030\" data-end=\"5199\"\u003eLiver transcriptomics show \u003cstrong data-start=\"5057\" data-end=\"5083\"\u003esuppressed lipogenesis\u003c\/strong\u003e and \u003cstrong data-start=\"5088\" data-end=\"5104\"\u003eenhanced FAO\u003c\/strong\u003e, with \u003cstrong data-start=\"5111\" data-end=\"5142\"\u003elower hepatic triglycerides\u003c\/strong\u003e and improved transaminases in models prone to steatosis.\u003c\/p\u003e\n\u003ch3 data-start=\"5201\" data-end=\"5229\"\u003e4.3 Exercise \u0026amp; Fitness\u003c\/h3\u003e\n\u003cp data-start=\"5230\" data-end=\"5406\"\u003eSkeletal muscle exhibits \u003cstrong data-start=\"5255\" data-end=\"5286\"\u003ePGC-1α\/ERR target induction\u003c\/strong\u003e, increased \u003cstrong data-start=\"5298\" data-end=\"5318\"\u003eOXPHOS complexes\u003c\/strong\u003e, and \u003cstrong data-start=\"5324\" data-end=\"5356\"\u003eimproved treadmill endurance\u003c\/strong\u003e—recapitulating aspects of \u003cstrong data-start=\"5383\" data-end=\"5405\"\u003eendurance training\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-start=\"5408\" data-end=\"5630\"\u003e\n\u003cp data-start=\"5410\" data-end=\"5630\"\u003e\u003cstrong data-start=\"5410\" data-end=\"5436\"\u003eEvidence quality note:\u003c\/strong\u003e Data for SLU-PP-332 are \u003cstrong data-start=\"5461\" data-end=\"5493\"\u003epre-clinical (rodents\/cells)\u003c\/strong\u003e and include \u003cstrong data-start=\"5506\" data-end=\"5545\"\u003einstitutional reports and preprints\u003c\/strong\u003e. Peer-reviewed, multicentre replication and \u003cstrong data-start=\"5590\" data-end=\"5607\"\u003ehuman studies\u003c\/strong\u003e are not yet available.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5632\" data-end=\"5635\"\u003e\n\u003ch2 data-start=\"5637\" data-end=\"5670\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5672\" data-end=\"6192\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5672\" data-end=\"5710\"\u003e\n\u003ctr data-start=\"5672\" data-end=\"5710\"\u003e\n\u003cth data-start=\"5672\" data-end=\"5680\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5680\" data-end=\"5692\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5692\" data-end=\"5710\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5725\" data-end=\"6192\"\u003e\n\u003ctr data-start=\"5725\" data-end=\"5825\"\u003e\n\u003ctd data-start=\"5725\" data-end=\"5750\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5727\" data-end=\"5749\"\u003eObesity\/overweight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5750\" data-end=\"5809\" data-col-size=\"md\"\u003e↑ EE without appetite suppression; oxidative remodelling\u003c\/td\u003e\n\u003ctd data-start=\"5809\" data-end=\"5825\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5826\" data-end=\"5895\"\u003e\n\u003ctd data-start=\"5826\" data-end=\"5843\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5828\" data-end=\"5842\"\u003eNAFLD\/NASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5843\" data-end=\"5879\" data-col-size=\"md\"\u003e↓ DNL, ↑ FAO; thermogenic support\u003c\/td\u003e\n\u003ctd data-start=\"5879\" data-end=\"5895\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5896\" data-end=\"5994\"\u003e\n\u003ctd data-start=\"5896\" data-end=\"5925\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5898\" data-end=\"5924\"\u003eT2D\/insulin resistance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5925\" data-end=\"5978\" data-col-size=\"md\"\u003eImproved insulin signalling \u0026amp; adipose inflammation\u003c\/td\u003e\n\u003ctd data-start=\"5978\" data-end=\"5994\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5995\" data-end=\"6101\"\u003e\n\u003ctd data-start=\"5995\" data-end=\"6028\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5997\" data-end=\"6027\"\u003eSarcopenic obesity\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6028\" data-end=\"6083\" data-col-size=\"md\"\u003eEndurance\/mitochondrial programs to augment function\u003c\/td\u003e\n\u003ctd data-start=\"6083\" data-end=\"6101\" data-col-size=\"sm\"\u003eConcept\/rodent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6102\" data-end=\"6192\"\u003e\n\u003ctd data-start=\"6102\" data-end=\"6132\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6104\" data-end=\"6131\"\u003eCardiometabolic fitness\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6132\" data-end=\"6174\" data-col-size=\"md\"\u003eExercise-mimetic transcriptional shifts\u003c\/td\u003e\n\u003ctd data-start=\"6174\" data-end=\"6192\" data-col-size=\"sm\"\u003eConcept\/rodent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6194\" data-end=\"6197\"\u003e\n\u003ch2 data-start=\"6199\" data-end=\"6228\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"6230\" data-end=\"6894\"\u003e\n\u003cli data-start=\"6230\" data-end=\"6287\"\u003e\n\u003cp data-start=\"6232\" data-end=\"6287\"\u003e\u003cstrong data-start=\"6232\" data-end=\"6249\"\u003eHuman safety:\u003c\/strong\u003e \u003cstrong data-start=\"6250\" data-end=\"6261\"\u003eUnknown\u003c\/strong\u003e (no clinical datasets).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6288\" data-end=\"6495\"\u003e\n\u003cp data-start=\"6290\" data-end=\"6495\"\u003e\u003cstrong data-start=\"6290\" data-end=\"6313\"\u003eOn-target cautions:\u003c\/strong\u003e \u003cstrong data-start=\"6314\" data-end=\"6354\"\u003eERRα\/γ are highly expressed in heart\u003c\/strong\u003e—chronic pan-ERR activation may alter \u003cstrong data-start=\"6392\" data-end=\"6440\"\u003ecardiac energetics\/arrhythmia susceptibility\u003c\/strong\u003e; careful CV monitoring would be required clinically.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6496\" data-end=\"6624\"\u003e\n\u003cp data-start=\"6498\" data-end=\"6624\"\u003e\u003cstrong data-start=\"6498\" data-end=\"6516\"\u003eEndocrine\/GRN:\u003c\/strong\u003e ERRs cross-talk with \u003cstrong data-start=\"6538\" data-end=\"6563\"\u003eestrogen\/thyroid\/PPAR\u003c\/strong\u003e programs; unintended transcriptional effects are possible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6625\" data-end=\"6798\"\u003e\n\u003cp data-start=\"6627\" data-end=\"6798\"\u003e\u003cstrong data-start=\"6627\" data-end=\"6641\"\u003eMetabolic:\u003c\/strong\u003e Excessive EE could \u003cstrong data-start=\"6661\" data-end=\"6704\"\u003eincrease resting heart rate\/temperature\u003c\/strong\u003e; \u003cstrong data-start=\"6706\" data-end=\"6746\"\u003eweight loss without intake reduction\u003c\/strong\u003eraises \u003cstrong data-start=\"6754\" data-end=\"6777\"\u003enutrient deficiency\u003c\/strong\u003e risk if unmanaged.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6799\" data-end=\"6894\"\u003e\n\u003cp data-start=\"6801\" data-end=\"6894\"\u003e\u003cstrong data-start=\"6801\" data-end=\"6831\"\u003eGenotoxicity\/oncogenicity:\u003c\/strong\u003e No GLP toxicology or carcinogenicity data have been disclosed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6896\" data-end=\"6925\"\u003e\u003cstrong data-start=\"6896\" data-end=\"6925\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6927\" data-end=\"7456\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6927\" data-end=\"7023\"\u003e\n\u003ctr data-start=\"6927\" data-end=\"7023\"\u003e\n\u003cth data-start=\"6927\" data-end=\"6937\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6937\" data-end=\"6964\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6939\" data-end=\"6963\"\u003eSLU-PP-332 (pan-ERR)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6964\" data-end=\"6991\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6966\" data-end=\"6990\"\u003eAICAR (AMPK agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6991\" data-end=\"7023\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6993\" data-end=\"7021\"\u003eGW501516 (PPARδ agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7042\" data-end=\"7456\"\u003e\n\u003ctr data-start=\"7042\" data-end=\"7150\"\u003e\n\u003ctd data-start=\"7042\" data-end=\"7054\" data-col-size=\"sm\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-start=\"7054\" data-end=\"7100\" data-col-size=\"sm\"\u003eTranscriptional “exercise” via \u003cstrong data-start=\"7087\" data-end=\"7099\"\u003eERRα\/β\/γ\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"7100\" data-end=\"7123\" data-col-size=\"sm\"\u003eEnergy stress sensor\u003c\/td\u003e\n\u003ctd data-start=\"7123\" data-end=\"7150\" data-col-size=\"sm\"\u003eFAO\/oxidative via PPARδ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7151\" data-end=\"7247\"\u003e\n\u003ctd data-start=\"7151\" data-end=\"7164\" data-col-size=\"sm\"\u003eHuman data\u003c\/td\u003e\n\u003ctd data-start=\"7164\" data-end=\"7175\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7166\" data-end=\"7174\"\u003eNone\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7175\" data-end=\"7203\" data-col-size=\"sm\"\u003eLimited (investigational)\u003c\/td\u003e\n\u003ctd data-start=\"7203\" data-end=\"7247\" data-col-size=\"sm\"\u003eNone (rodent tumor signals at high dose)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7248\" data-end=\"7380\"\u003e\n\u003ctd data-start=\"7248\" data-end=\"7260\" data-col-size=\"sm\"\u003eCV impact\u003c\/td\u003e\n\u003ctd data-start=\"7260\" data-end=\"7302\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7262\" data-end=\"7301\"\u003ePotential cardiac energetic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7302\" data-end=\"7338\" data-col-size=\"sm\"\u003eBrady-like signals in some models\u003c\/td\u003e\n\u003ctd data-start=\"7338\" data-end=\"7380\" data-col-size=\"sm\"\u003e↑ endurance; tumor concerns in rodents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7381\" data-end=\"7456\"\u003e\n\u003ctd data-start=\"7381\" data-end=\"7401\" data-col-size=\"sm\"\u003eRegulatory status\u003c\/td\u003e\n\u003ctd data-start=\"7401\" data-end=\"7416\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003ctd data-start=\"7416\" data-end=\"7434\" data-col-size=\"sm\"\u003eInvestigational\u003c\/td\u003e\n\u003ctd data-start=\"7434\" data-end=\"7456\" data-col-size=\"sm\"\u003eAbandoned (safety)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7458\" data-end=\"7461\"\u003e\n\u003ch2 data-start=\"7463\" data-end=\"7489\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7491\" data-end=\"7778\"\u003e\n\u003cli data-start=\"7491\" data-end=\"7515\"\u003e\n\u003cp data-start=\"7493\" data-end=\"7515\"\u003e\u003cstrong data-start=\"7493\" data-end=\"7507\"\u003eApprovals:\u003c\/strong\u003e None.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7516\" data-end=\"7658\"\u003e\n\u003cp data-start=\"7518\" data-end=\"7658\"\u003e\u003cstrong data-start=\"7518\" data-end=\"7540\"\u003eDevelopment stage:\u003c\/strong\u003e \u003cstrong data-start=\"7541\" data-end=\"7588\"\u003eDiscovery\/lead-optimization to pre-clinical\u003c\/strong\u003e space; \u003cstrong data-start=\"7596\" data-end=\"7626\"\u003eno registered human trials\u003c\/strong\u003e publicly reported as of 2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7659\" data-end=\"7778\"\u003e\n\u003cp data-start=\"7661\" data-end=\"7778\"\u003e\u003cstrong data-start=\"7661\" data-end=\"7672\"\u003eAccess:\u003c\/strong\u003e Not available as a medicine; any grey-market product should be considered \u003cstrong data-start=\"7747\" data-end=\"7762\"\u003eunregulated\u003c\/strong\u003e and \u003cstrong data-start=\"7767\" data-end=\"7777\"\u003eunsafe\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7780\" data-end=\"7783\"\u003e\n\u003ch2 data-start=\"7785\" data-end=\"7808\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7810\" data-end=\"8612\"\u003e\n\u003cli data-start=\"7810\" data-end=\"7957\"\u003e\n\u003cp data-start=\"7812\" data-end=\"7957\"\u003e\u003cstrong data-start=\"7812\" data-end=\"7840\"\u003eSelectivity engineering:\u003c\/strong\u003e Bias toward \u003cstrong data-start=\"7853\" data-end=\"7863\"\u003eERRα\/γ\u003c\/strong\u003e or tissue-targeted delivery (e.g., \u003cstrong data-start=\"7899\" data-end=\"7929\"\u003emuscle- or liver-targeting\u003c\/strong\u003e) to improve benefit–risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7958\" data-end=\"8130\"\u003e\n\u003cp data-start=\"7960\" data-end=\"8130\"\u003e\u003cstrong data-start=\"7960\" data-end=\"7989\"\u003eTranslational biomarkers:\u003c\/strong\u003e \u003cstrong data-start=\"7990\" data-end=\"8083\"\u003eIndirect calorimetry (VO₂), acyl-carnitine profiles, mtDNA copy number, OXPHOS proteomics\u003c\/strong\u003e, and \u003cstrong data-start=\"8089\" data-end=\"8107\"\u003eliver MRI-PDFF\u003c\/strong\u003e for early human PoC.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8131\" data-end=\"8279\"\u003e\n\u003cp data-start=\"8133\" data-end=\"8279\"\u003e\u003cstrong data-start=\"8133\" data-end=\"8160\"\u003eCombination strategies:\u003c\/strong\u003e Pair with \u003cstrong data-start=\"8171\" data-end=\"8188\"\u003ediet\/exercise\u003c\/strong\u003e, \u003cstrong data-start=\"8190\" data-end=\"8212\"\u003eGLP-1\/GIP agonists\u003c\/strong\u003e (metabolic) or \u003cstrong data-start=\"8228\" data-end=\"8238\"\u003eSGLT2i\u003c\/strong\u003e to diversify cardiometabolic benefits.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8280\" data-end=\"8441\"\u003e\n\u003cp data-start=\"8282\" data-end=\"8441\"\u003e\u003cstrong data-start=\"8282\" data-end=\"8301\"\u003eSafety program:\u003c\/strong\u003e \u003cstrong data-start=\"8302\" data-end=\"8331\"\u003eCardiac electrophysiology\u003c\/strong\u003e, \u003cstrong data-start=\"8333\" data-end=\"8359\"\u003emitochondrial toxicity\u003c\/strong\u003e, \u003cstrong data-start=\"8361\" data-end=\"8402\"\u003eoff-target nuclear-receptor profiling\u003c\/strong\u003e, and \u003cstrong data-start=\"8408\" data-end=\"8423\"\u003echronic tox\u003c\/strong\u003e in two species.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8442\" data-end=\"8612\"\u003e\n\u003cp data-start=\"8444\" data-end=\"8612\"\u003e\u003cstrong data-start=\"8444\" data-end=\"8468\"\u003ePhenotype targeting:\u003c\/strong\u003e Visceral-predominant obesity, \u003cstrong data-start=\"8499\" data-end=\"8525\"\u003eNAFLD with low fitness\u003c\/strong\u003e, and \u003cstrong data-start=\"8531\" data-end=\"8566\"\u003estatin-intolerant dysmetabolism\u003c\/strong\u003e where oxidative re-programming is compelling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8614\" data-end=\"8617\"\u003e\n\u003ch3 data-start=\"8619\" data-end=\"8642\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8644\" data-end=\"9299\"\u003e\n\u003cli data-start=\"8644\" data-end=\"8781\"\u003e\n\u003cp data-start=\"8646\" data-end=\"8781\"\u003eSaint Louis University research communications and preprints describing \u003cstrong data-start=\"8718\" data-end=\"8732\"\u003eSLU-PP-332\u003c\/strong\u003e as a pan-ERR exercise-mimetic (mouse studies).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8782\" data-end=\"8920\"\u003e\n\u003cp data-start=\"8784\" data-end=\"8920\"\u003e\u003cstrong data-start=\"8784\" data-end=\"8833\"\u003eCell Metabolism; Nature Reviews Endocrinology\u003c\/strong\u003e — Reviews on \u003cstrong data-start=\"8847\" data-end=\"8861\"\u003eERR–PGC-1α\u003c\/strong\u003e control of oxidative metabolism and exercise adaptation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8921\" data-end=\"9055\"\u003e\n\u003cp data-start=\"8923\" data-end=\"9055\"\u003e\u003cstrong data-start=\"8923\" data-end=\"8974\"\u003eMolecular Metabolism; Journal of Lipid Research\u003c\/strong\u003e — ERR regulation of \u003cstrong data-start=\"8995\" data-end=\"9012\"\u003ethermogenesis\u003c\/strong\u003e and \u003cstrong data-start=\"9017\" data-end=\"9031\"\u003elipid flux\u003c\/strong\u003e in adipose and liver.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9056\" data-end=\"9192\"\u003e\n\u003cp data-start=\"9058\" data-end=\"9192\"\u003e\u003cstrong data-start=\"9058\" data-end=\"9122\"\u003eJournal of Physiology; Nature Reviews Molecular Cell Biology\u003c\/strong\u003e — \u003cstrong data-start=\"9125\" data-end=\"9135\"\u003ePGC-1α\u003c\/strong\u003e in endurance adaptations and mitochondrial biogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9193\" data-end=\"9299\"\u003e\n\u003cp data-start=\"9195\" data-end=\"9299\"\u003e\u003cstrong data-start=\"9195\" data-end=\"9222\"\u003eCardiovascular Research\u003c\/strong\u003e — Cardiac roles of \u003cstrong data-start=\"9242\" data-end=\"9252\"\u003eERRα\/γ\u003c\/strong\u003e and implications for pharmacologic activation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684852527442,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/SLU-pp-332_10mg.png?v=1770834857"},{"product_id":"cagrilintide-10mg","title":"Cagrilintide 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"866\" data-start=\"288\"\u003e\u003cstrong data-end=\"304\" data-start=\"288\"\u003eCagrilintide\u003c\/strong\u003e is a novel, long-acting amylin analogue under development primarily for \u003cstrong data-end=\"399\" data-start=\"377\"\u003eobesity management\u003c\/strong\u003e and \u003cstrong data-end=\"439\" data-start=\"404\"\u003etype 2 diabetes mellitus (T2DM)\u003c\/strong\u003e. It mimics and extends the physiological effects of endogenous amylin—a pancreatic hormone co-secreted with insulin—by regulating \u003cstrong data-end=\"616\" data-start=\"570\"\u003egastric emptying, satiety, and food intake\u003c\/strong\u003e. Cagrilintide is administered \u003cstrong data-end=\"662\" data-start=\"647\"\u003eonce weekly\u003c\/strong\u003e via subcutaneous injection and is being investigated both as \u003cstrong data-end=\"739\" data-start=\"724\"\u003emonotherapy\u003c\/strong\u003e and in \u003cstrong data-end=\"779\" data-start=\"747\"\u003ecombination with semaglutide\u003c\/strong\u003e, a GLP-1 receptor agonist, in a dual-agonist formulation referred to as \u003cstrong data-end=\"865\" data-start=\"852\"\u003eCagriSema\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"871\" data-start=\"868\"\u003e\n\u003ch2 class=\"\" data-end=\"902\" data-start=\"873\"\u003e\u003cstrong data-end=\"902\" data-start=\"876\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"983\" data-start=\"904\"\u003eCagrilintide exerts its pharmacologic effects through dual receptor activation:\u003c\/p\u003e\n\u003cul data-end=\"1213\" data-start=\"985\"\u003e\n\u003cli class=\"\" data-end=\"1103\" data-start=\"985\"\u003e\n\u003cp class=\"\" data-end=\"1103\" data-start=\"987\"\u003e\u003cstrong data-end=\"1015\" data-start=\"987\"\u003eAmylin Receptor Agonism:\u003c\/strong\u003e Enhances satiety, delays gastric emptying, and reduces postprandial glucagon secretion.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1213\" data-start=\"1104\"\u003e\n\u003cp class=\"\" data-end=\"1213\" data-start=\"1106\"\u003e\u003cstrong data-end=\"1155\" data-start=\"1106\"\u003eCalcitonin Receptor Agonism (minor activity):\u003c\/strong\u003e Contributes to appetite regulation and weight modulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1411\" data-start=\"1215\"\u003eThis dual activity distinguishes cagrilintide from endogenous amylin and its predecessor, \u003cstrong data-end=\"1320\" data-start=\"1305\"\u003epramlintide\u003c\/strong\u003e, by offering \u003cstrong data-end=\"1367\" data-start=\"1334\"\u003eprolonged receptor engagement\u003c\/strong\u003e and \u003cstrong data-end=\"1410\" data-start=\"1372\"\u003egreater weight-reduction potential\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"1416\" data-start=\"1413\"\u003e\n\u003ch2 class=\"\" data-end=\"1445\" data-start=\"1418\"\u003e\u003cstrong data-end=\"1445\" data-start=\"1421\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"1478\" data-start=\"1447\"\u003e\u003cstrong data-end=\"1478\" data-start=\"1451\"\u003e3.1. Monotherapy Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1710\" data-start=\"1480\"\u003eIn a \u003cstrong data-end=\"1533\" data-start=\"1485\"\u003ePhase 2 randomized, placebo-controlled trial\u003c\/strong\u003e (Marre et al., \u003cem data-end=\"1561\" data-start=\"1549\"\u003eThe Lancet\u003c\/em\u003e, 2021), over 300 adults with obesity received varying doses of cagrilintide (0.3–4.5 mg) or liraglutide 3.0 mg daily for 26 weeks. Results included:\u003c\/p\u003e\n\u003cul data-end=\"1962\" data-start=\"1712\"\u003e\n\u003cli class=\"\" data-end=\"1791\" data-start=\"1712\"\u003e\n\u003cp class=\"\" data-end=\"1791\" data-start=\"1714\"\u003e\u003cstrong data-end=\"1739\" data-start=\"1714\"\u003eMean weight reduction\u003c\/strong\u003e of up to \u003cstrong data-end=\"1757\" data-start=\"1749\"\u003e8.1%\u003c\/strong\u003e at the highest cagrilintide dose.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1860\" data-start=\"1792\"\u003e\n\u003cp class=\"\" data-end=\"1860\" data-start=\"1794\"\u003eSuperior weight loss versus liraglutide (6.8%) and placebo (1.6%).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1962\" data-start=\"1861\"\u003e\n\u003cp class=\"\" data-end=\"1962\" data-start=\"1863\"\u003eImprovements in waist circumference, systolic blood pressure, and patient-reported appetite scores.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2008\" data-start=\"1964\"\u003e\u003cstrong data-end=\"2008\" data-start=\"1968\"\u003e3.2. Combination Therapy (CagriSema)\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"2083\" data-start=\"2010\"\u003eCagrilintide has shown remarkable synergy when combined with semaglutide:\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2159\" data-start=\"2085\"\u003e\u003cstrong data-end=\"2159\" data-start=\"2090\"\u003ePhase 2 Trial (CagriSema vs. Semaglutide vs. Cagrilintide Alone):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2378\" data-start=\"2161\"\u003e\n\u003cli class=\"\" data-end=\"2222\" data-start=\"2161\"\u003e\n\u003cp class=\"\" data-end=\"2222\" data-start=\"2163\"\u003ePopulation: Adults with \u003cstrong data-end=\"2221\" data-start=\"2187\"\u003eT2DM and overweight or obesity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2244\" data-start=\"2223\"\u003e\n\u003cp class=\"\" data-end=\"2244\" data-start=\"2225\"\u003eDuration: 32 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2245\"\u003e\n\u003cp class=\"\" data-end=\"2256\" data-start=\"2247\"\u003eFindings:\u003c\/p\u003e\n\u003cul data-end=\"2378\" data-start=\"2259\"\u003e\n\u003cli class=\"\" data-end=\"2295\" data-start=\"2259\"\u003e\n\u003cp class=\"\" data-end=\"2295\" data-start=\"2261\"\u003e\u003cstrong data-end=\"2275\" data-start=\"2261\"\u003eCagriSema:\u003c\/strong\u003e ~15.6% weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2336\" data-start=\"2298\"\u003e\n\u003cp class=\"\" data-end=\"2336\" data-start=\"2300\"\u003e\u003cstrong data-end=\"2329\" data-start=\"2300\"\u003eSemaglutide 2.4 mg alone:\u003c\/strong\u003e ~5.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2378\" data-start=\"2339\"\u003e\n\u003cp class=\"\" data-end=\"2378\" data-start=\"2341\"\u003e\u003cstrong data-end=\"2371\" data-start=\"2341\"\u003eCagrilintide 2.4 mg alone:\u003c\/strong\u003e ~8.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"2477\" data-start=\"2380\"\u003eThis indicates an additive or possibly synergistic effect when both agents are used concurrently.\u003c\/p\u003e\n\u003ch4 class=\"\" data-end=\"2534\" data-start=\"2479\"\u003e\u003cstrong data-end=\"2534\" data-start=\"2484\"\u003eREDEFINE 2 Phase 3 Trial (2024, Novo Nordisk):\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-end=\"2771\" data-start=\"2536\"\u003e\n\u003cli class=\"\" data-end=\"2585\" data-start=\"2536\"\u003e\n\u003cp class=\"\" data-end=\"2585\" data-start=\"2538\"\u003ePopulation: Adults with T2DM and BMI ≥27 kg\/m².\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2607\" data-start=\"2586\"\u003e\n\u003cp class=\"\" data-end=\"2607\" data-start=\"2588\"\u003eDuration: 68 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2608\"\u003e\n\u003cp class=\"\" data-end=\"2618\" data-start=\"2610\"\u003eResults:\u003c\/p\u003e\n\u003cul data-end=\"2771\" data-start=\"2621\"\u003e\n\u003cli class=\"\" data-end=\"2667\" data-start=\"2621\"\u003e\n\u003cp class=\"\" data-end=\"2667\" data-start=\"2623\"\u003e\u003cstrong data-end=\"2643\" data-start=\"2623\"\u003eCagriSema group:\u003c\/strong\u003e 15.7% mean weight loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2696\" data-start=\"2670\"\u003e\n\u003cp class=\"\" data-end=\"2696\" data-start=\"2672\"\u003e\u003cstrong data-end=\"2690\" data-start=\"2672\"\u003ePlacebo group:\u003c\/strong\u003e 3.1%.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2771\" data-start=\"2699\"\u003e\n\u003cp class=\"\" data-end=\"2771\" data-start=\"2701\"\u003eAlso noted improvements in HbA1c, fasting glucose, and lipid profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2776\" data-start=\"2773\"\u003e\n\u003ch2 class=\"\" data-end=\"2811\" data-start=\"2778\"\u003e\u003cstrong data-end=\"2811\" data-start=\"2781\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2886\" data-start=\"2813\"\u003eAcross studies, cagrilintide has demonstrated a favorable safety profile:\u003c\/p\u003e\n\u003cul data-end=\"3302\" data-start=\"2888\"\u003e\n\u003cli class=\"\" data-end=\"3011\" data-start=\"2888\"\u003e\n\u003cp class=\"\" data-end=\"3011\" data-start=\"2890\"\u003e\u003cstrong data-end=\"2921\" data-start=\"2890\"\u003eMost common adverse events:\u003c\/strong\u003e Gastrointestinal symptoms (nausea, vomiting, constipation), dose-dependent and transient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3096\" data-start=\"3012\"\u003e\n\u003cp class=\"\" data-end=\"3096\" data-start=\"3014\"\u003e\u003cstrong data-end=\"3036\" data-start=\"3014\"\u003eHypoglycemia risk:\u003c\/strong\u003e Minimal when used without insulin or insulin secretagogues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3209\" data-start=\"3097\"\u003e\n\u003cp class=\"\" data-end=\"3209\" data-start=\"3099\"\u003e\u003cstrong data-end=\"3118\" data-start=\"3099\"\u003eCardiac safety:\u003c\/strong\u003e No significant QT prolongation; no increase in major adverse cardiovascular events (MACE).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3302\" data-start=\"3210\"\u003e\n\u003cp class=\"\" data-end=\"3302\" data-start=\"3212\"\u003e\u003cstrong data-end=\"3231\" data-start=\"3212\"\u003eImmunogenicity:\u003c\/strong\u003e Low incidence of anti-drug antibodies; no impact on efficacy observed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3307\" data-start=\"3304\"\u003e\n\u003ch2 class=\"\" data-end=\"3335\" data-start=\"3309\"\u003e\u003cstrong data-end=\"3335\" data-start=\"3312\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"3604\" data-start=\"3337\"\u003e\n\u003cli class=\"\" data-end=\"3409\" data-start=\"3337\"\u003e\n\u003cp class=\"\" data-end=\"3409\" data-start=\"3339\"\u003e\u003cstrong data-end=\"3353\" data-start=\"3339\"\u003eHalf-life:\u003c\/strong\u003e Approximately 150 hours, supporting once-weekly dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3495\" data-start=\"3410\"\u003e\n\u003cp class=\"\" data-end=\"3495\" data-start=\"3412\"\u003e\u003cstrong data-end=\"3427\" data-start=\"3412\"\u003eAbsorption:\u003c\/strong\u003e Delayed Tmax (~72 hours), with stable weekly plasma concentrations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3604\" data-start=\"3496\"\u003e\n\u003cp class=\"\" data-end=\"3604\" data-start=\"3498\"\u003e\u003cstrong data-end=\"3514\" data-start=\"3498\"\u003eElimination:\u003c\/strong\u003e Renal excretion is minor; no dose adjustment required for mild\/moderate renal impairment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3609\" data-start=\"3606\"\u003e\n\u003ch2 class=\"\" data-end=\"3660\" data-start=\"3611\"\u003e\u003cstrong data-end=\"3660\" data-start=\"3614\"\u003e6. Clinical Development and Future Outlook\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3786\" data-start=\"3662\"\u003eCagrilintide is part of Novo Nordisk’s \u003cstrong data-end=\"3736\" data-start=\"3701\"\u003eREDEFINE clinical trial program\u003c\/strong\u003e, targeting both monotherapy and dual-therapy use:\u003c\/p\u003e\n\u003cul data-end=\"4152\" data-start=\"3788\"\u003e\n\u003cli class=\"\" data-end=\"3897\" data-start=\"3788\"\u003e\n\u003cp class=\"\" data-end=\"3897\" data-start=\"3790\"\u003e\u003cstrong data-end=\"3814\" data-start=\"3790\"\u003eREDEFINE 1–6 Trials:\u003c\/strong\u003e Ongoing Phase 3 studies in various patient subgroups (obesity, T2DM, prediabetes).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4027\" data-start=\"3898\"\u003e\n\u003cp class=\"\" data-end=\"4027\" data-start=\"3900\"\u003e\u003cstrong data-end=\"3922\" data-start=\"3900\"\u003eCombination Focus:\u003c\/strong\u003e CagriSema is expected to be a \u003cstrong data-end=\"3984\" data-start=\"3953\"\u003efirst-in-class dual peptide\u003c\/strong\u003e for chronic weight and glucose management.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4152\" data-start=\"4028\"\u003e\n\u003cp class=\"\" data-end=\"4152\" data-start=\"4030\"\u003e\u003cstrong data-end=\"4056\" data-start=\"4030\"\u003ePotential indications:\u003c\/strong\u003e Obesity, T2DM, metabolic syndrome, possibly for cardiovascular risk reduction pending outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"4299\" data-start=\"4154\"\u003eIf regulatory approval is granted, \u003cstrong data-end=\"4241\" data-start=\"4189\"\u003eCagriSema could redefine obesity pharmacotherapy\u003c\/strong\u003e, offering superior efficacy with manageable tolerability.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4304\" data-start=\"4301\"\u003e\n\u003ch2 class=\"\" data-end=\"4326\" data-start=\"4306\"\u003e\u003cstrong data-end=\"4326\" data-start=\"4309\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"4702\" data-start=\"4328\"\u003eCagrilintide represents a significant advancement in metabolic therapeutics. Its ability to induce meaningful weight loss, especially in combination with GLP-1 agonists like semaglutide, places it at the forefront of next-generation obesity and diabetes management. Pending long-term safety and cardiovascular outcome data, it holds promise for widespread clinical adoption.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"4707\" data-start=\"4704\"\u003e\n\u003ch2 class=\"\" data-end=\"4730\" data-start=\"4709\"\u003e\u003cstrong data-end=\"4730\" data-start=\"4712\"\u003eKey References\u003c\/strong\u003e\u003c\/h2\u003e\n\u003col data-end=\"5111\" data-start=\"4732\"\u003e\n\u003cli class=\"\" data-end=\"4807\" data-start=\"4732\"\u003e\n\u003cp class=\"\" data-end=\"4807\" data-start=\"4735\"\u003eMarre M, et al. \u003cem data-end=\"4763\" data-start=\"4751\"\u003eThe Lancet\u003c\/em\u003e, 2021. DOI: 10.1016\/S2213-8587(21)00203-0\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4881\" data-start=\"4808\"\u003e\n\u003cp class=\"\" data-end=\"4881\" data-start=\"4811\"\u003eDavies M, et al. \u003cem data-end=\"4857\" data-start=\"4828\"\u003eLancet Diabetes Endocrinol.\u003c\/em\u003e, 2023. PMID: 37364590\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4960\" data-start=\"4882\"\u003e\n\u003cp class=\"\" data-end=\"4960\" data-start=\"4885\"\u003eRosenstock J, et al. \u003cem data-end=\"4928\" data-start=\"4906\"\u003eDiabetes Obes Metab.\u003c\/em\u003e, 2023. DOI: 10.1111\/dom.15951\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5024\" data-start=\"4961\"\u003e\n\u003cp class=\"\" data-end=\"5024\" data-start=\"4964\"\u003eNovo Nordisk press release: REDEFINE 2 Trial Results, 2024\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5111\" data-start=\"5025\"\u003e\n\u003cp class=\"\" data-end=\"5111\" data-start=\"5028\"\u003eWadden TA, et al. \u003cem data-end=\"5055\" data-start=\"5046\"\u003eObesity\u003c\/em\u003e, 2024. Clinical implications of CagriSema dual therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684860260690,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/cagrilintide_10mg.png?v=1770834903"},{"product_id":"semax-10mg-vial","title":"Semax 10mg vial","description":"\u003cp data-start=\"417\" data-end=\"855\" class=\"\"\u003e\u003cstrong data-start=\"417\" data-end=\"426\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan\u003eFO\u003c\/span\u003eR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"417\" data-end=\"855\" class=\"\"\u003e\u003cstrong data-start=\"417\" data-end=\"426\"\u003eSemax\u003c\/strong\u003e is a synthetic peptide developed in Russia in the 1980s by the Institute of Molecular Genetics at the Russian Academy of Sciences. Originally intended for stroke treatment, Semax is recognized for its nootropic, neuroprotective, neurogenic, and cognitive-enhancing properties. It is utilized clinically in Russia and parts of Eastern Europe, notably prescribed for cognitive disorders, brain injuries, and neurological deficits.\u003c\/p\u003e\n\u003chr data-start=\"857\" data-end=\"860\" class=\"\"\u003e\n\u003ch2 data-start=\"862\" data-end=\"904\" class=\"\"\u003eChemical and Pharmacological Background\u003c\/h2\u003e\n\u003cul data-start=\"906\" data-end=\"1284\"\u003e\n\u003cli data-start=\"906\" data-end=\"1058\" class=\"\"\u003e\n\u003cp data-start=\"908\" data-end=\"1058\" class=\"\"\u003e\u003cstrong data-start=\"908\" data-end=\"932\"\u003eChemical Composition\u003c\/strong\u003e: Synthetic analogue of adrenocorticotropic hormone (ACTH); specifically, the peptide ACTH(4-10): Met-Glu-His-Phe-Pro-Gly-Pro.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1059\" data-end=\"1109\" class=\"\"\u003e\n\u003cp data-start=\"1061\" data-end=\"1109\" class=\"\"\u003e\u003cstrong data-start=\"1061\" data-end=\"1081\"\u003eMolecular Weight\u003c\/strong\u003e: Approximately 813.9 g\/mol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1110\" data-end=\"1198\" class=\"\"\u003e\n\u003cp data-start=\"1112\" data-end=\"1198\" class=\"\"\u003e\u003cstrong data-start=\"1112\" data-end=\"1130\"\u003eClassification\u003c\/strong\u003e: Synthetic peptide; neuropeptide, nootropic, neuroprotective agent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1199\" data-end=\"1284\" class=\"\"\u003e\n\u003cp data-start=\"1201\" data-end=\"1284\" class=\"\"\u003e\u003cstrong data-start=\"1201\" data-end=\"1217\"\u003eFormulations\u003c\/strong\u003e: Commonly administered intranasally or via subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1286\" data-end=\"1289\" class=\"\"\u003e\n\u003ch2 data-start=\"1291\" data-end=\"1314\" class=\"\"\u003eMechanisms of Action\u003c\/h2\u003e\n\u003cp data-start=\"1316\" data-end=\"1399\" class=\"\"\u003eSemax operates via multiple neurochemical pathways, explaining its diverse effects:\u003c\/p\u003e\n\u003ch3 data-start=\"1401\" data-end=\"1442\" class=\"\"\u003e1. \u003cstrong data-start=\"1408\" data-end=\"1442\"\u003eNeurotrophic Factor Modulation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1443\" data-end=\"1648\"\u003e\n\u003cli data-start=\"1443\" data-end=\"1555\" class=\"\"\u003e\n\u003cp data-start=\"1445\" data-end=\"1555\" class=\"\"\u003eSignificantly increases levels of \u003cstrong data-start=\"1479\" data-end=\"1523\"\u003eBrain-Derived Neurotrophic Factor (BDNF)\u003c\/strong\u003e and other neurotrophic factors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1556\" data-end=\"1648\" class=\"\"\u003e\n\u003cp data-start=\"1558\" data-end=\"1648\" class=\"\"\u003ePromotes neurogenesis, neuronal differentiation, survival, and improved neural plasticity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1650\" data-end=\"1710\" class=\"\"\u003e2. \u003cstrong data-start=\"1657\" data-end=\"1710\"\u003eNeuromodulation of Dopamine and Serotonin Systems\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1711\" data-end=\"1841\"\u003e\n\u003cli data-start=\"1711\" data-end=\"1841\" class=\"\"\u003e\n\u003cp data-start=\"1713\" data-end=\"1841\" class=\"\"\u003eEnhances dopamine and serotonin signaling pathways, potentially improving mood, motivation, cognition, and emotional regulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1843\" data-end=\"1884\" class=\"\"\u003e3. \u003cstrong data-start=\"1850\" data-end=\"1884\"\u003eMelanocortin System Activation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"1885\" data-end=\"2042\"\u003e\n\u003cli data-start=\"1885\" data-end=\"2042\" class=\"\"\u003e\n\u003cp data-start=\"1887\" data-end=\"2042\" class=\"\"\u003eAs a melanocortin receptor agonist (specifically MC4 receptors), Semax modulates stress responses, attention, memory, anxiety levels, and immune responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2044\" data-end=\"2103\" class=\"\"\u003e4. \u003cstrong data-start=\"2051\" data-end=\"2103\"\u003eAnti-Inflammatory and Neuroprotective Properties\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2104\" data-end=\"2273\"\u003e\n\u003cli data-start=\"2104\" data-end=\"2183\" class=\"\"\u003e\n\u003cp data-start=\"2106\" data-end=\"2183\" class=\"\"\u003eReduces oxidative stress, inflammation, and neuronal damage following injury.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2184\" data-end=\"2273\" class=\"\"\u003e\n\u003cp data-start=\"2186\" data-end=\"2273\" class=\"\"\u003ePromotes recovery after traumatic brain injury, stroke, ischemia, or neurodegeneration.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2275\" data-end=\"2315\" class=\"\"\u003e5. \u003cstrong data-start=\"2282\" data-end=\"2315\"\u003eEnhanced Cerebral Circulation\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2316\" data-end=\"2472\"\u003e\n\u003cli data-start=\"2316\" data-end=\"2472\" class=\"\"\u003e\n\u003cp data-start=\"2318\" data-end=\"2472\" class=\"\"\u003eImproves blood flow in cerebral tissues, delivering oxygen and nutrients more effectively, thus potentially improving cognitive function and brain health.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2474\" data-end=\"2477\" class=\"\"\u003e\n\u003ch2 data-start=\"2479\" data-end=\"2529\" class=\"\"\u003ePotential Therapeutic and Clinical Applications\u003c\/h2\u003e\n\u003cp data-start=\"2531\" data-end=\"2646\" class=\"\"\u003eSemax is clinically approved and prescribed in Russia for numerous neurological conditions and cognitive disorders:\u003c\/p\u003e\n\u003ch3 data-start=\"2648\" data-end=\"2697\" class=\"\"\u003e1. \u003cstrong data-start=\"2655\" data-end=\"2697\"\u003eCognitive Enhancement (Nootropic Uses)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2698\" data-end=\"2861\"\u003e\n\u003cli data-start=\"2698\" data-end=\"2766\" class=\"\"\u003e\n\u003cp data-start=\"2700\" data-end=\"2766\" class=\"\"\u003eImproves attention, memory, mental clarity, and learning capacity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2767\" data-end=\"2861\" class=\"\"\u003e\n\u003cp data-start=\"2769\" data-end=\"2861\" class=\"\"\u003ePotential applications for cognitive decline, ADHD, memory impairment, or cognitive fatigue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2863\" data-end=\"2902\" class=\"\"\u003e2. \u003cstrong data-start=\"2870\" data-end=\"2902\"\u003eStroke and Cerebral Ischemia\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"2903\" data-end=\"3076\"\u003e\n\u003cli data-start=\"2903\" data-end=\"3009\" class=\"\"\u003e\n\u003cp data-start=\"2905\" data-end=\"3009\" class=\"\"\u003ePromotes recovery of neurological functions after stroke, transient ischemic attacks, or brain ischemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3010\" data-end=\"3076\" class=\"\"\u003e\n\u003cp data-start=\"3012\" data-end=\"3076\" class=\"\"\u003eClinically employed to reduce neurological deficits post-stroke.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3078\" data-end=\"3135\" class=\"\"\u003e3. \u003cstrong data-start=\"3085\" data-end=\"3135\"\u003eNeuroprotection and Neurodegenerative Diseases\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3136\" data-end=\"3284\"\u003e\n\u003cli data-start=\"3136\" data-end=\"3284\" class=\"\"\u003e\n\u003cp data-start=\"3138\" data-end=\"3284\" class=\"\"\u003ePotential therapeutic use in Parkinson’s, Alzheimer’s, dementia, or age-related cognitive decline due to neuroprotective and neurotrophic effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3286\" data-end=\"3343\" class=\"\"\u003e4. \u003cstrong data-start=\"3293\" data-end=\"3343\"\u003eAnxiety, Stress Management, and Mood Disorders\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3344\" data-end=\"3540\"\u003e\n\u003cli data-start=\"3344\" data-end=\"3438\" class=\"\"\u003e\n\u003cp data-start=\"3346\" data-end=\"3438\" class=\"\"\u003eReduces anxiety and stress symptoms via modulation of stress-related neurochemical pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3439\" data-end=\"3540\" class=\"\"\u003e\n\u003cp data-start=\"3441\" data-end=\"3540\" class=\"\"\u003ePotential use in anxiety disorders, mild depression, PTSD, or stress-induced cognitive dysfunction.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3542\" data-end=\"3581\" class=\"\"\u003e5. \u003cstrong data-start=\"3549\" data-end=\"3581\"\u003eTraumatic Brain Injury (TBI)\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cul data-start=\"3582\" data-end=\"3693\"\u003e\n\u003cli data-start=\"3582\" data-end=\"3693\" class=\"\"\u003e\n\u003cp data-start=\"3584\" data-end=\"3693\" class=\"\"\u003eSupports neuronal regeneration, reduces inflammation, and improves outcomes following traumatic brain injury.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3695\" data-end=\"3698\" class=\"\"\u003e\n\u003ch2 data-start=\"3700\" data-end=\"3739\" class=\"\"\u003eDosage and Administration Guidelines\u003c\/h2\u003e\n\u003cp data-start=\"3741\" data-end=\"3842\" class=\"\"\u003eSemax is primarily administered intranasally or subcutaneously due to limited bioavailability orally.\u003c\/p\u003e\n\u003cp data-start=\"3844\" data-end=\"3902\" class=\"\"\u003e\u003cstrong data-start=\"3844\" data-end=\"3902\"\u003eTypical Dosage Ranges (Clinical and Experimental Use):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3904\" data-end=\"4317\"\u003e\n\u003cli data-start=\"3904\" data-end=\"4165\" class=\"\"\u003e\n\u003cp data-start=\"3906\" data-end=\"3936\" class=\"\"\u003e\u003cstrong data-start=\"3906\" data-end=\"3936\"\u003eIntranasal Administration:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3939\" data-end=\"4165\"\u003e\n\u003cli data-start=\"3939\" data-end=\"4030\" class=\"\"\u003e\n\u003cp data-start=\"3941\" data-end=\"4030\" class=\"\"\u003e\u003cstrong data-start=\"3941\" data-end=\"3958\"\u003eStandard Dose\u003c\/strong\u003e: 50–150 mcg per spray, usually 1–3 sprays per nostril, 1–3 times daily.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4033\" data-end=\"4165\" class=\"\"\u003e\n\u003cp data-start=\"4035\" data-end=\"4165\" class=\"\"\u003e\u003cstrong data-start=\"4035\" data-end=\"4050\"\u003eDaily Total\u003c\/strong\u003e: Usually ranges from 300 mcg to 900 mcg\/day; higher doses occasionally used temporarily under medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4167\" data-end=\"4317\" class=\"\"\u003e\n\u003cp data-start=\"4169\" data-end=\"4240\" class=\"\"\u003e\u003cstrong data-start=\"4169\" data-end=\"4240\"\u003eSubcutaneous Injection (less common outside clinical environments):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4243\" data-end=\"4317\"\u003e\n\u003cli data-start=\"4243\" data-end=\"4317\" class=\"\"\u003e\n\u003cp data-start=\"4245\" data-end=\"4317\" class=\"\"\u003e\u003cstrong data-start=\"4245\" data-end=\"4263\"\u003eTypical Dosage\u003c\/strong\u003e: 200–1000 mcg\/day, usually split into 1–3 injections.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4319\" data-end=\"4338\" class=\"\"\u003e\u003cstrong data-start=\"4319\" data-end=\"4338\"\u003eCycle Duration:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4339\" data-end=\"4457\"\u003e\n\u003cli data-start=\"4339\" data-end=\"4457\" class=\"\"\u003e\n\u003cp data-start=\"4341\" data-end=\"4457\" class=\"\"\u003eTypically used in cycles lasting several weeks, followed by breaks to monitor effects and avoid potential tolerance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4459\" data-end=\"4462\" class=\"\"\u003e\n\u003ch2 data-start=\"4464\" data-end=\"4508\" class=\"\"\u003eSafety Profile and Potential Side Effects\u003c\/h2\u003e\n\u003cp data-start=\"4510\" data-end=\"4609\" class=\"\"\u003eSemax demonstrates a notably favorable safety profile, with minimal side effects commonly reported:\u003c\/p\u003e\n\u003ch3 data-start=\"4611\" data-end=\"4665\" class=\"\"\u003e\n\u003cstrong data-start=\"4615\" data-end=\"4664\"\u003eCommon Side Effects (Rare and Generally Mild)\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4666\" data-end=\"4782\"\u003e\n\u003cli data-start=\"4666\" data-end=\"4724\" class=\"\"\u003e\n\u003cp data-start=\"4668\" data-end=\"4724\" class=\"\"\u003eMild nasal irritation or discomfort from intranasal use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4725\" data-end=\"4782\" class=\"\"\u003e\n\u003cp data-start=\"4727\" data-end=\"4782\" class=\"\"\u003eMild headache or transient dizziness (rarely reported).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4784\" data-end=\"4816\" class=\"\"\u003e\n\u003cstrong data-start=\"4788\" data-end=\"4815\"\u003eSerious Adverse Effects\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4817\" data-end=\"4861\"\u003e\n\u003cli data-start=\"4817\" data-end=\"4861\" class=\"\"\u003e\n\u003cp data-start=\"4819\" data-end=\"4861\" class=\"\"\u003eRare or unreported at therapeutic dosages.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4863\" data-end=\"4896\" class=\"\"\u003e\n\u003cstrong data-start=\"4867\" data-end=\"4895\"\u003eTolerance and Dependence\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"4897\" data-end=\"5001\"\u003e\n\u003cli data-start=\"4897\" data-end=\"5001\" class=\"\"\u003e\n\u003cp data-start=\"4899\" data-end=\"5001\" class=\"\"\u003eCurrently no strong evidence suggesting tolerance, addiction, or withdrawal risk at therapeutic doses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5003\" data-end=\"5033\" class=\"\"\u003e\n\u003cstrong data-start=\"5007\" data-end=\"5032\"\u003eLong-Term Safety Data\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5034\" data-end=\"5144\"\u003e\n\u003cli data-start=\"5034\" data-end=\"5144\" class=\"\"\u003e\n\u003cp data-start=\"5036\" data-end=\"5144\" class=\"\"\u003eLimited, but clinical experience in Russia suggests generally safe long-term usage with medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5146\" data-end=\"5149\" class=\"\"\u003e\n\u003ch2 data-start=\"5151\" data-end=\"5188\" class=\"\"\u003eContraindications and Interactions\u003c\/h2\u003e\n\u003ch3 data-start=\"5190\" data-end=\"5216\" class=\"\"\u003e\n\u003cstrong data-start=\"5194\" data-end=\"5215\"\u003eContraindications\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5217\" data-end=\"5342\"\u003e\n\u003cli data-start=\"5217\" data-end=\"5281\" class=\"\"\u003e\n\u003cp data-start=\"5219\" data-end=\"5281\" class=\"\"\u003eHypersensitivity or allergic reactions to peptide-based drugs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5282\" data-end=\"5342\" class=\"\"\u003e\n\u003cp data-start=\"5284\" data-end=\"5342\" class=\"\"\u003eSevere psychiatric conditions without medical supervision.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5344\" data-end=\"5365\" class=\"\"\u003e\n\u003cstrong data-start=\"5348\" data-end=\"5364\"\u003eInteractions\u003c\/strong\u003e:\u003c\/h3\u003e\n\u003cul data-start=\"5366\" data-end=\"5587\"\u003e\n\u003cli data-start=\"5366\" data-end=\"5406\" class=\"\"\u003e\n\u003cp data-start=\"5368\" data-end=\"5406\" class=\"\"\u003eFew well-documented drug interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5407\" data-end=\"5587\" class=\"\"\u003e\n\u003cp data-start=\"5409\" data-end=\"5587\" class=\"\"\u003eDue to neurochemical modulation, caution is advised if combining Semax with psychotropic medications (SSRIs, MAOIs, stimulants) due to theoretical (though rarely reported) risks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5589\" data-end=\"5592\" class=\"\"\u003e\n\u003ch2 data-start=\"5594\" data-end=\"5624\" class=\"\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-start=\"5626\" data-end=\"6162\"\u003e\n\u003cli data-start=\"5626\" data-end=\"5764\" class=\"\"\u003e\n\u003cp data-start=\"5628\" data-end=\"5764\" class=\"\"\u003e\u003cstrong data-start=\"5628\" data-end=\"5655\"\u003eRussia \u0026amp; Eastern Europe\u003c\/strong\u003e: Semax is officially approved and prescribed by medical practitioners, available as prescription medication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5765\" data-end=\"5997\" class=\"\"\u003e\n\u003cp data-start=\"5767\" data-end=\"5997\" class=\"\"\u003e\u003cstrong data-start=\"5767\" data-end=\"5807\"\u003eUnited States, Canada, EU, Australia\u003c\/strong\u003e: Not approved or regulated as a pharmaceutical. It is usually marketed through specialty supplement retailers or research chemical suppliers, typically labeled “for research purposes only.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5998\" data-end=\"6162\" class=\"\"\u003e\n\u003cp data-start=\"6000\" data-end=\"6162\" class=\"\"\u003e\u003cstrong data-start=\"6000\" data-end=\"6037\"\u003eWADA (Sports Regulatory Agencies)\u003c\/strong\u003e: Semax is currently \u003cstrong data-start=\"6058\" data-end=\"6065\"\u003enot\u003c\/strong\u003e listed as a prohibited substance by WADA, but always consult updated prohibited substance lists.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6164\" data-end=\"6167\" class=\"\"\u003e\n\u003ch2 data-start=\"6169\" data-end=\"6211\" class=\"\"\u003eClinical and Scientific Research Status\u003c\/h2\u003e\n\u003cp data-start=\"6213\" data-end=\"6332\" class=\"\"\u003eSemax has been studied primarily in Russian research, though growing interest internationally has increased visibility:\u003c\/p\u003e\n\u003ch3 data-start=\"6334\" data-end=\"6383\" class=\"\"\u003e\u003cstrong data-start=\"6338\" data-end=\"6383\"\u003eClinical Studies and Scientific Findings:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"6384\" data-end=\"6623\"\u003e\n\u003cli data-start=\"6384\" data-end=\"6533\" class=\"\"\u003e\n\u003cp data-start=\"6386\" data-end=\"6533\" class=\"\"\u003eSignificant increases in BDNF, neuronal growth, cognitive function, and reductions in oxidative stress demonstrated in animal and clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6534\" data-end=\"6623\" class=\"\"\u003e\n\u003cp data-start=\"6536\" data-end=\"6623\" class=\"\"\u003eProven efficacy in stroke recovery and cognitive disorders in Russian clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"6625\" data-end=\"6676\" class=\"\"\u003e\u003cstrong data-start=\"6629\" data-end=\"6676\"\u003eLimitations and Needs for Further Research:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"6677\" data-end=\"6931\"\u003e\n\u003cli data-start=\"6677\" data-end=\"6784\" class=\"\"\u003e\n\u003cp data-start=\"6679\" data-end=\"6784\" class=\"\"\u003eLimited availability of large-scale, randomized, placebo-controlled clinical trials in Western countries.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6785\" data-end=\"6931\" class=\"\"\u003e\n\u003cp data-start=\"6787\" data-end=\"6931\" class=\"\"\u003eMore comprehensive international research is needed to confirm the extent of therapeutic efficacy, optimal dosing, and long-term safety profile.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6933\" data-end=\"6936\" class=\"\"\u003e\n\u003ch2 data-start=\"6938\" data-end=\"6980\" class=\"\"\u003eSummary of Potential Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"overflow-x-auto contain-inline-size\"\u003e\n\u003ctable data-start=\"6982\" data-end=\"7754\"\u003e\n\u003cthead data-start=\"6982\" data-end=\"7091\"\u003e\n\u003ctr data-start=\"6982\" data-end=\"7091\"\u003e\n\u003cth data-start=\"6982\" data-end=\"7037\"\u003e\u003cstrong data-start=\"6984\" data-end=\"7006\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7037\" data-end=\"7091\"\u003e\u003cstrong data-start=\"7039\" data-end=\"7069\"\u003ePossible Risks\/Limitations\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7202\" data-end=\"7754\"\u003e\n\u003ctr data-start=\"7202\" data-end=\"7311\"\u003e\n\u003ctd\u003eCognitive enhancement (memory, attention, focus)\u003c\/td\u003e\n\u003ctd\u003eLimited robust international clinical data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7312\" data-end=\"7421\"\u003e\n\u003ctd\u003eNeuroprotection, neurogenesis, anti-aging potential\u003c\/td\u003e\n\u003ctd\u003eLimited long-term safety evidence internationally\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7422\" data-end=\"7531\"\u003e\n\u003ctd\u003eImproved mood, reduced anxiety, emotional stability\u003c\/td\u003e\n\u003ctd\u003eRare mild nasal irritation or transient headache\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7532\" data-end=\"7641\"\u003e\n\u003ctd\u003eStroke, ischemia, TBI recovery\u003c\/td\u003e\n\u003ctd\u003eRegulatory status uncertain outside Eastern Europe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7642\" data-end=\"7754\"\u003e\n\u003ctd\u003eLow incidence of side effects\u003c\/td\u003e\n\u003ctd\u003eFew documented drug interactions, but caution advised\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7756\" data-end=\"7759\" class=\"\"\u003e\n\u003ch2 data-start=\"7761\" data-end=\"7798\" class=\"\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-start=\"7800\" data-end=\"8442\"\u003e\n\u003cli data-start=\"7800\" data-end=\"7983\" class=\"\"\u003e\n\u003cp data-start=\"7802\" data-end=\"7983\" class=\"\"\u003eAshmarin, I. P., et al. (1997). \"Semax, an analog of ACTH(4–10) with cognitive-enhancing and neuroprotective properties.\" \u003cstrong data-start=\"7924\" data-end=\"7966\"\u003eNeuroscience and Behavioral Physiology\u003c\/strong\u003e, 27(6), 607–612.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7984\" data-end=\"8152\" class=\"\"\u003e\n\u003cp data-start=\"7986\" data-end=\"8152\" class=\"\"\u003eLevitskaya, N. G., et al. (2004). \"Neuroprotective and nootropic effects of Semax in ischemic stroke.\" \u003cstrong data-start=\"8089\" data-end=\"8138\"\u003eBulletin of Experimental Biology and Medicine\u003c\/strong\u003e, 138(1), 1–4.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8153\" data-end=\"8326\" class=\"\"\u003e\n\u003cp data-start=\"8155\" data-end=\"8326\" class=\"\"\u003eKaplan, A. Y., et al. (1996). \"Semax attenuates cognitive impairment after acute ischemic stroke.\" \u003cstrong data-start=\"8254\" data-end=\"8311\"\u003eZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova\u003c\/strong\u003e, 96(9), 22–25.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684862751058,"sku":"10","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Semax_10mg.png?v=1770834924"},{"product_id":"selank-10mg-vial","title":"Selank 10mg vial","description":"\u003cp data-start=\"63\" data-end=\"467\"\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"63\" data-end=\"467\"\u003e\u003cstrong\u003eSelank\u003c\/strong\u003e is a synthetic peptide developed in Russia. It is a modified form of the naturally occurring peptide \u003cem data-start=\"171\" data-end=\"180\"\u003eTuftsin\u003c\/em\u003e, which plays a role in immune system regulation. Selank has been studied for its nootropic (cognitive-enhancing), anxiolytic (anxiety-reducing), and neuroprotective properties. It is often used as a research chemical and is sometimes utilized off-label for various therapeutic purposes.\u003c\/p\u003e\n\u003ch3 data-start=\"469\" data-end=\"498\"\u003e2. \u003cstrong data-start=\"476\" data-end=\"498\"\u003eChemical Structure\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"499\" data-end=\"562\"\u003eSelank is a synthetic peptide consisting of seven amino acids:\u003c\/p\u003e\n\u003cul data-start=\"563\" data-end=\"700\"\u003e\n\u003cli data-start=\"563\" data-end=\"700\"\u003e\n\u003cstrong data-start=\"565\" data-end=\"577\"\u003eSequence\u003c\/strong\u003e: Thr-Lys-Pro-Arg-Pro-Gly-Pro. This sequence is a derivative of tuftsin, which is known for its immune-boosting properties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"702\" data-end=\"732\"\u003e3. \u003cstrong data-start=\"709\" data-end=\"732\"\u003eMechanism of Action\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"733\" data-end=\"892\"\u003eSelank works through various mechanisms in the brain, primarily affecting neurotransmitter systems. The key ways in which Selank may exert its effects include:\u003c\/p\u003e\n\u003cul data-start=\"894\" data-end=\"1672\"\u003e\n\u003cli data-start=\"894\" data-end=\"1088\"\u003e\n\u003cp data-start=\"896\" data-end=\"1088\"\u003e\u003cstrong data-start=\"896\" data-end=\"937\"\u003eModulation of Neurotransmitter Levels\u003c\/strong\u003e: Selank has been found to increase serotonin, dopamine, and other neurotransmitter levels, promoting a balanced mood and potentially reducing anxiety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1092\" data-end=\"1306\"\u003e\n\u003cp data-start=\"1094\" data-end=\"1306\"\u003e\u003cstrong data-start=\"1094\" data-end=\"1116\"\u003eAnxiolytic Effects\u003c\/strong\u003e: Selank may help in the regulation of the body's stress response. It has shown potential for reducing symptoms of anxiety and panic attacks by modulating GABAergic and serotonergic systems.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1308\" data-end=\"1484\"\u003e\n\u003cp data-start=\"1310\" data-end=\"1484\"\u003e\u003cstrong data-start=\"1310\" data-end=\"1335\"\u003eCognitive Enhancement\u003c\/strong\u003e: Some studies suggest that Selank can improve memory, learning, and concentration by supporting brain function, especially during periods of stress.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1486\" data-end=\"1672\"\u003e\n\u003cp data-start=\"1488\" data-end=\"1672\"\u003e\u003cstrong data-start=\"1488\" data-end=\"1507\"\u003eNeuroprotection\u003c\/strong\u003e: There is evidence that Selank can have protective effects on brain cells, improving brain function under stress and promoting neurogenesis (growth of new neurons).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1674\" data-end=\"1703\"\u003e4. \u003cstrong data-start=\"1681\" data-end=\"1703\"\u003eBenefits of Selank\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003ch4 data-start=\"1705\" data-end=\"1745\"\u003e\u003cstrong data-start=\"1710\" data-end=\"1745\"\u003eAnxiolytic\/Anti-Anxiety Effects\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"1746\" data-end=\"1956\"\u003eSelank is commonly used as an anxiety-reducing agent. Research suggests that it can decrease symptoms of both chronic and acute anxiety by modulating the levels of neurotransmitters involved in stress response.\u003c\/p\u003e\n\u003ch4 data-start=\"1958\" data-end=\"1988\"\u003e\u003cstrong data-start=\"1963\" data-end=\"1988\"\u003eCognitive Enhancement\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"1989\" data-end=\"2067\"\u003eIt is reported that Selank may have a positive impact on cognition, including:\u003c\/p\u003e\n\u003cul data-start=\"2068\" data-end=\"2164\"\u003e\n\u003cli data-start=\"2068\" data-end=\"2095\"\u003eImproved memory retention\u003c\/li\u003e\n\u003cli data-start=\"2096\" data-end=\"2131\"\u003eIncreased focus and concentration\u003c\/li\u003e\n\u003cli data-start=\"2132\" data-end=\"2164\"\u003eEnhanced learning capabilities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"2166\" data-end=\"2191\"\u003e\u003cstrong data-start=\"2171\" data-end=\"2191\"\u003eMood Enhancement\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2192\" data-end=\"2356\"\u003eIn addition to reducing anxiety, Selank can help improve mood and promote a sense of well-being, which may be helpful for individuals suffering from mood disorders.\u003c\/p\u003e\n\u003ch4 data-start=\"2358\" data-end=\"2382\"\u003e\u003cstrong data-start=\"2363\" data-end=\"2382\"\u003eNeuroprotection\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2383\" data-end=\"2580\"\u003eSelank might offer some protection to the brain, especially under conditions of mental or physical stress. It may help preserve cognitive function and protect against age-related cognitive decline.\u003c\/p\u003e\n\u003ch4 data-start=\"2582\" data-end=\"2615\"\u003e\u003cstrong data-start=\"2587\" data-end=\"2615\"\u003eImmunomodulatory Effects\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cp data-start=\"2616\" data-end=\"2778\"\u003eDue to its relation to tuftsin, Selank may have mild immunomodulatory effects, which could enhance the immune system's function and overall response to pathogens.\u003c\/p\u003e\n\u003ch3 data-start=\"2780\" data-end=\"2812\"\u003e5. \u003cstrong data-start=\"2787\" data-end=\"2812\"\u003ePossible Side Effects\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"2813\" data-end=\"2928\"\u003eWhile Selank is generally considered to be well-tolerated, some individuals may experience side effects, including:\u003c\/p\u003e\n\u003cul data-start=\"2929\" data-end=\"2992\"\u003e\n\u003cli data-start=\"2929\" data-end=\"2944\"\u003e\u003cstrong data-start=\"2931\" data-end=\"2944\"\u003eHeadaches\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2945\" data-end=\"2960\"\u003e\u003cstrong data-start=\"2947\" data-end=\"2960\"\u003eDizziness\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2961\" data-end=\"2978\"\u003e\u003cstrong data-start=\"2963\" data-end=\"2978\"\u003eMild nausea\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli data-start=\"2979\" data-end=\"2992\"\u003e\u003cstrong data-start=\"2981\" data-end=\"2992\"\u003eFatigue\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2994\" data-end=\"3044\"\u003eThese side effects are usually mild and transient.\u003c\/p\u003e\n\u003ch3 data-start=\"3046\" data-end=\"3082\"\u003e6. \u003cstrong data-start=\"3053\" data-end=\"3082\"\u003eAdministration and Dosage\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3083\" data-end=\"3286\"\u003eSelank is typically administered through subcutaneous injection or intranasal (nasal spray) administration. The most common method for self-administration is via nasal spray, as it is easy and effective.\u003c\/p\u003e\n\u003ch4 data-start=\"3288\" data-end=\"3330\"\u003e\n\u003cstrong data-start=\"3293\" data-end=\"3329\"\u003eDosage (Typical Recommendations)\u003c\/strong\u003e:\u003c\/h4\u003e\n\u003cul data-start=\"3331\" data-end=\"3508\"\u003e\n\u003cli data-start=\"3331\" data-end=\"3435\"\u003e\n\u003cstrong data-start=\"3333\" data-end=\"3347\"\u003eIntranasal\u003c\/strong\u003e: A common dosage range is 300-600 mcg per dose, usually administered 1-2 times per day.\u003c\/li\u003e\n\u003cli data-start=\"3436\" data-end=\"3508\"\u003e\n\u003cstrong data-start=\"3438\" data-end=\"3464\"\u003eSubcutaneous Injection\u003c\/strong\u003e: 250-500 mcg per dose, once or twice daily.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3704\" data-end=\"3747\"\u003e7. \u003cstrong data-start=\"3711\" data-end=\"3747\"\u003eHalf-Life and Duration of Action\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3748\" data-end=\"3958\"\u003eThe half-life of Selank is relatively short, around 2 to 4 hours. Therefore, its effects are generally not long-lasting, which is why repeated doses throughout the day may be necessary to maintain its benefits.\u003c\/p\u003e\n\u003ch3 data-start=\"3960\" data-end=\"3983\"\u003e8. \u003cstrong data-start=\"3967\" data-end=\"3983\"\u003eLegal Status\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"3984\" data-end=\"4178\"\u003eSelank is not approved for use in many countries, including the United States and Europe, but it is available for research purposes. \u003cmeta charset=\"UTF-8\"\u003e\u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e \u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e\u003cstrong data-start=\"288\" data-end=\"328\"\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"288\" data-end=\"435\"\u003e\u003cstrong data-start=\"288\" data-end=\"328\"\u003eKovalenko, A., \u0026amp; Erofeev, A. (2002).\u003c\/strong\u003e \u003cem data-start=\"329\" data-end=\"392\"\u003e\"Pharmacological and clinical aspects of the peptide Selank.\"\u003c\/em\u003e \u003cstrong data-start=\"393\" data-end=\"435\"\u003eBiochemistry (Moscow), 67(5), 516-522.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"616\" data-end=\"798\"\u003e\u003cstrong data-start=\"616\" data-end=\"662\"\u003eTikhonova, L. A., \u0026amp; Frolova, S. N. (2007).\u003c\/strong\u003e \u003cem data-start=\"663\" data-end=\"738\"\u003e\"Selank as a neuroprotective agent and modulator of the stress response.\"\u003c\/em\u003e\u003cstrong data-start=\"739\" data-end=\"798\"\u003eNeuroscience and Behavioral Physiology, 37(7), 653-658.\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-start=\"926\" data-end=\"1070\"\u003e\u003cstrong data-start=\"926\" data-end=\"972\"\u003eBukhman, V. Y., \u0026amp; Yakovleva, T. I. (2000).\u003c\/strong\u003e \u003cem data-start=\"973\" data-end=\"1030\"\u003e\"Selank and its effects on the central nervous system.\"\u003c\/em\u003e \u003cstrong data-start=\"1031\" data-end=\"1070\"\u003eNeurochemical Journal, 5(1), 50-55.\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp data-start=\"1231\" data-end=\"1384\"\u003e\u003cstrong data-start=\"1231\" data-end=\"1279\"\u003eAkhmadulina, L. A., \u0026amp; Zukhrim, V. A. (2010).\u003c\/strong\u003e \u003cem data-start=\"1280\" data-end=\"1339\"\u003e\"The impact of Selank on serotonin and dopamine systems.\"\u003c\/em\u003e \u003cstrong data-start=\"1340\" data-end=\"1384\"\u003eJournal of Neuroscience, 15(2), 181-189.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"3984\" data-end=\"4178\"\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684862980434,"sku":null,"price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Selank_10mg.png?v=1770834924"},{"product_id":"melanotan-ii-10mg-vial","title":"Melanotan-II 10mg vial","description":"\u003cp data-start=\"421\" data-end=\"782\" class=\"\"\u003e\u003cstrong data-start=\"421\" data-end=\"445\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan\u003eF\u003c\/span\u003eOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"421\" data-end=\"782\" class=\"\"\u003e\u003cstrong data-start=\"421\" data-end=\"445\"\u003eMelanotan-II (MT-II)\u003c\/strong\u003e is a synthetic cyclic heptapeptide analog of the naturally occurring alpha-melanocyte-stimulating hormone (\u003cspan class=\"katex\"\u003e\u003cspan class=\"katex-mathml\"\u003e\u003cmath xmlns=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"\u003e\u003csemantics\u003e\u003cmrow\u003e\u003cmi\u003eα\u003c\/mi\u003e\u003c\/mrow\u003e\u003c\/semantics\u003e\u003c\/math\u003e\u003c\/span\u003e\u003cspan class=\"katex-html\" aria-hidden=\"true\"\u003e\u003cspan class=\"base\"\u003e\u003cspan class=\"strut\"\u003e\u003c\/span\u003e\u003cspan class=\"mord mathnormal\"\u003eα\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e-MSH). It was originally developed as a \u003cstrong data-start=\"603\" data-end=\"614\"\u003etanning\u003c\/strong\u003e agent—stimulating melanin production to darken skin pigmentation—and has also been studied for its potential \u003cstrong data-start=\"724\" data-end=\"739\"\u003eaphrodisiac\u003c\/strong\u003e and \u003cstrong data-start=\"744\" data-end=\"773\"\u003esexual function–enhancing\u003c\/strong\u003e effects.\u003c\/p\u003e\n\u003cul data-start=\"784\" data-end=\"1070\"\u003e\n\u003cli data-start=\"784\" data-end=\"831\" class=\"\"\u003e\n\u003cp data-start=\"786\" data-end=\"831\" class=\"\"\u003e\u003cstrong data-start=\"786\" data-end=\"802\"\u003eCommon Names\u003c\/strong\u003e: Melanotan-II, MT-2, MT-II\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"832\" data-end=\"939\" class=\"\"\u003e\n\u003cp data-start=\"834\" data-end=\"939\" class=\"\"\u003e\u003cstrong data-start=\"834\" data-end=\"861\"\u003eChemical Classification\u003c\/strong\u003e: Synthetic peptide analog of \u003cspan class=\"katex\"\u003e\u003cspan class=\"katex-mathml\"\u003e\u003cmath xmlns=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"\u003e\u003csemantics\u003e\u003cmrow\u003e\u003cmi\u003eα\u003c\/mi\u003e\u003c\/mrow\u003e\u003c\/semantics\u003e\u003c\/math\u003e\u003c\/span\u003e\u003cspan class=\"katex-html\" aria-hidden=\"true\"\u003e\u003cspan class=\"base\"\u003e\u003cspan class=\"strut\"\u003e\u003c\/span\u003e\u003cspan class=\"mord mathnormal\"\u003eα\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e-MSH (melanocortin receptor agonist)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"940\" data-end=\"1070\" class=\"\"\u003e\n\u003cp data-start=\"942\" data-end=\"1070\" class=\"\"\u003e\u003cstrong data-start=\"942\" data-end=\"960\"\u003eAdministration\u003c\/strong\u003e: Primarily subcutaneous injection, though nasal spray forms are sometimes sold (with questionable absorption)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1072\" data-end=\"1075\" class=\"\"\u003e\n\u003ch2 data-start=\"1077\" data-end=\"1102\" class=\"\"\u003e2. Mechanism of Action\u003c\/h2\u003e\n\u003cp data-start=\"1104\" data-end=\"1225\" class=\"\"\u003eMT-II binds to and activates \u003cstrong data-start=\"1133\" data-end=\"1159\"\u003emelanocortin receptors\u003c\/strong\u003e (notably \u003cstrong data-start=\"1169\" data-end=\"1177\"\u003eMC1R\u003c\/strong\u003e and \u003cstrong data-start=\"1182\" data-end=\"1190\"\u003eMC4R\u003c\/strong\u003e). These receptors are involved in:\u003c\/p\u003e\n\u003col data-start=\"1227\" data-end=\"1699\"\u003e\n\u003cli data-start=\"1227\" data-end=\"1407\" class=\"\"\u003e\n\u003cp data-start=\"1230\" data-end=\"1269\" class=\"\"\u003e\u003cstrong data-start=\"1230\" data-end=\"1247\"\u003eMelanogenesis\u003c\/strong\u003e (Skin Pigmentation)\u003c\/p\u003e\n\u003cul data-start=\"1273\" data-end=\"1407\"\u003e\n\u003cli data-start=\"1273\" data-end=\"1407\" class=\"\"\u003e\n\u003cp data-start=\"1275\" data-end=\"1407\" class=\"\"\u003e\u003cstrong data-start=\"1275\" data-end=\"1283\"\u003eMC1R\u003c\/strong\u003e activation in melanocytes increases the production of \u003cstrong data-start=\"1338\" data-end=\"1349\"\u003emelanin\u003c\/strong\u003e, the pigment responsible for skin tanning and hair color.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1409\" data-end=\"1588\" class=\"\"\u003e\n\u003cp data-start=\"1412\" data-end=\"1443\" class=\"\"\u003e\u003cstrong data-start=\"1412\" data-end=\"1441\"\u003eLibido and Sexual Arousal\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"1447\" data-end=\"1588\"\u003e\n\u003cli data-start=\"1447\" data-end=\"1588\" class=\"\"\u003e\n\u003cp data-start=\"1449\" data-end=\"1588\" class=\"\"\u003e\u003cstrong data-start=\"1449\" data-end=\"1457\"\u003eMC4R\u003c\/strong\u003e activation is implicated in \u003cstrong data-start=\"1486\" data-end=\"1505\"\u003esexual function\u003c\/strong\u003e and \u003cstrong data-start=\"1510\" data-end=\"1532\"\u003eenergy homeostasis\u003c\/strong\u003e. Some individuals report stronger libido and erections.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1590\" data-end=\"1699\" class=\"\"\u003e\n\u003cp data-start=\"1593\" data-end=\"1629\" class=\"\"\u003e\u003cstrong data-start=\"1593\" data-end=\"1627\"\u003eAppetite and Energy Regulation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"1633\" data-end=\"1699\"\u003e\n\u003cli data-start=\"1633\" data-end=\"1699\" class=\"\"\u003e\n\u003cp data-start=\"1635\" data-end=\"1699\" class=\"\"\u003eCertain melanocortin receptors influence satiety and metabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"1701\" data-end=\"1704\" class=\"\"\u003e\n\u003ch2 data-start=\"1706\" data-end=\"1739\" class=\"\"\u003e3. Potential Benefits and Uses\u003c\/h2\u003e\n\u003col data-start=\"1741\" data-end=\"2555\"\u003e\n\u003cli data-start=\"1741\" data-end=\"2167\" class=\"\"\u003e\n\u003cp data-start=\"1744\" data-end=\"1777\" class=\"\"\u003e\u003cstrong data-start=\"1744\" data-end=\"1775\"\u003eTanning \/ Skin Pigmentation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"1781\" data-end=\"2167\"\u003e\n\u003cli data-start=\"1781\" data-end=\"1977\" class=\"\"\u003e\n\u003cp data-start=\"1783\" data-end=\"1977\" class=\"\"\u003e\u003cstrong data-start=\"1783\" data-end=\"1807\"\u003eMain Intended Effect\u003c\/strong\u003e: MT-II can increase melanin production, potentially providing a tanned appearance with less sun exposure and possibly some \u003cstrong data-start=\"1931\" data-end=\"1950\"\u003ephotoprotection\u003c\/strong\u003e against harmful UV rays.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1981\" data-end=\"2167\" class=\"\"\u003e\n\u003cp data-start=\"1983\" data-end=\"2167\" class=\"\"\u003e\u003cstrong data-start=\"1983\" data-end=\"2003\"\u003eResearch Context\u003c\/strong\u003e: Initial research at the University of Arizona aimed to reduce the incidence of skin cancer by inducing tanning (protective melanin) without excessive UV exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2169\" data-end=\"2439\" class=\"\"\u003e\n\u003cp data-start=\"2172\" data-end=\"2196\" class=\"\"\u003e\u003cstrong data-start=\"2172\" data-end=\"2194\"\u003eSexual Enhancement\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2200\" data-end=\"2439\"\u003e\n\u003cli data-start=\"2200\" data-end=\"2309\" class=\"\"\u003e\n\u003cp data-start=\"2202\" data-end=\"2309\" class=\"\"\u003eIn both men and women, anecdotal and some clinical evidence suggest increased \u003cstrong data-start=\"2280\" data-end=\"2290\"\u003elibido\u003c\/strong\u003e and \u003cstrong data-start=\"2295\" data-end=\"2306\"\u003earousal\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2313\" data-end=\"2439\" class=\"\"\u003e\n\u003cp data-start=\"2315\" data-end=\"2439\" class=\"\"\u003e\u003cstrong data-start=\"2315\" data-end=\"2336\"\u003eErectile Function\u003c\/strong\u003e: MT-II has been studied in erectile dysfunction contexts and sometimes used off-label for this reason.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2441\" data-end=\"2555\" class=\"\"\u003e\n\u003cp data-start=\"2444\" data-end=\"2482\" class=\"\"\u003e\u003cstrong data-start=\"2444\" data-end=\"2480\"\u003eAppetite Suppression (Anecdotal)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2486\" data-end=\"2555\"\u003e\n\u003cli data-start=\"2486\" data-end=\"2555\" class=\"\"\u003e\n\u003cp data-start=\"2488\" data-end=\"2555\" class=\"\"\u003eSome users report decreased hunger, though this effect is variable.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"2557\" data-end=\"2560\" class=\"\"\u003e\n\u003ch2 data-start=\"2562\" data-end=\"2620\" class=\"\"\u003e4. Administration and Dosing (Experimental \/ Anecdotal)\u003c\/h2\u003e\n\u003cblockquote data-start=\"2622\" data-end=\"2809\"\u003e\n\u003cp data-start=\"2624\" data-end=\"2809\" class=\"\"\u003e\u003cstrong data-start=\"2624\" data-end=\"2638\"\u003eDisclaimer\u003c\/strong\u003e: No standardized, FDA-approved dosing guidelines exist for Melanotan-II. The information below is derived from unregulated use, anecdotal reports, and limited research.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cul data-start=\"2811\" data-end=\"3274\"\u003e\n\u003cli data-start=\"2811\" data-end=\"2868\" class=\"\"\u003e\n\u003cp data-start=\"2813\" data-end=\"2868\" class=\"\"\u003e\u003cstrong data-start=\"2813\" data-end=\"2839\"\u003eSubcutaneous Injection\u003c\/strong\u003e: Most commonly used route.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2869\" data-end=\"2999\" class=\"\"\u003e\n\u003cp data-start=\"2871\" data-end=\"2999\" class=\"\"\u003e\u003cstrong data-start=\"2871\" data-end=\"2897\"\u003eTypical “Starter” Dose\u003c\/strong\u003e: Ranges from \u003cstrong data-start=\"2911\" data-end=\"2929\"\u003e0.25 to 0.5 mg\u003c\/strong\u003e daily or every other day. Users often start low to gauge tolerance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3000\" data-end=\"3122\" class=\"\"\u003e\n\u003cp data-start=\"3002\" data-end=\"3122\" class=\"\"\u003e\u003cstrong data-start=\"3002\" data-end=\"3022\"\u003eMaintenance Dose\u003c\/strong\u003e: Once desired skin tone is achieved, some individuals reduce frequency to \u003cstrong data-start=\"3097\" data-end=\"3110\"\u003e0.25–1 mg\u003c\/strong\u003e per week.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3123\" data-end=\"3274\" class=\"\"\u003e\n\u003cp data-start=\"3125\" data-end=\"3274\" class=\"\"\u003e\u003cstrong data-start=\"3125\" data-end=\"3142\"\u003eLoading Phase\u003c\/strong\u003e: Higher-frequency, small daily doses (0.25–0.5 mg) for 1–2 weeks until desired pigment is noticed, followed by a maintenance phase.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3276\" data-end=\"3298\" class=\"\"\u003eKey Considerations\u003c\/h3\u003e\n\u003cul data-start=\"3299\" data-end=\"3694\"\u003e\n\u003cli data-start=\"3299\" data-end=\"3387\" class=\"\"\u003e\n\u003cp data-start=\"3301\" data-end=\"3387\" class=\"\"\u003e\u003cstrong data-start=\"3301\" data-end=\"3325\"\u003eIndividual Variation\u003c\/strong\u003e: Skin type, body weight, and general tolerance vary widely.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3388\" data-end=\"3537\" class=\"\"\u003e\n\u003cp data-start=\"3390\" data-end=\"3537\" class=\"\"\u003e\u003cstrong data-start=\"3390\" data-end=\"3405\"\u003eUV Exposure\u003c\/strong\u003e: Users typically still expose themselves to some UV (sunlight or tanning beds) to “activate” melanin production more effectively.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3538\" data-end=\"3694\" class=\"\"\u003e\n\u003cp data-start=\"3540\" data-end=\"3694\" class=\"\"\u003e\u003cstrong data-start=\"3540\" data-end=\"3579\"\u003eOver-Darkening or Hyperpigmentation\u003c\/strong\u003e: Excess use can cause uneven pigmentation or darkening of moles, freckles, and possible hyperpigmentation patches.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3696\" data-end=\"3699\" class=\"\"\u003e\n\u003ch2 data-start=\"3701\" data-end=\"3748\" class=\"\"\u003e5. Safety Profile and Potential Side Effects\u003c\/h2\u003e\n\u003ch3 data-start=\"3750\" data-end=\"3778\" class=\"\"\u003e5.1. Common Side Effects\u003c\/h3\u003e\n\u003cul data-start=\"3779\" data-end=\"4090\"\u003e\n\u003cli data-start=\"3779\" data-end=\"3912\" class=\"\"\u003e\n\u003cp data-start=\"3781\" data-end=\"3912\" class=\"\"\u003e\u003cstrong data-start=\"3781\" data-end=\"3804\"\u003eNausea and Flushing\u003c\/strong\u003e: A characteristic “flushing” feeling and mild nausea often accompany doses, especially at higher amounts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3913\" data-end=\"4014\" class=\"\"\u003e\n\u003cp data-start=\"3915\" data-end=\"4014\" class=\"\"\u003e\u003cstrong data-start=\"3915\" data-end=\"3935\"\u003eAppetite Changes\u003c\/strong\u003e: Appetite suppression (most common) or occasionally mild stomach discomfort.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4015\" data-end=\"4090\" class=\"\"\u003e\n\u003cp data-start=\"4017\" data-end=\"4090\" class=\"\"\u003e\u003cstrong data-start=\"4017\" data-end=\"4046\"\u003eFacial Flushing \/ Redness\u003c\/strong\u003e: Particularly shortly after administration.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4092\" data-end=\"4128\" class=\"\"\u003e5.2. Pigmentation Irregularities\u003c\/h3\u003e\n\u003cul data-start=\"4129\" data-end=\"4319\"\u003e\n\u003cli data-start=\"4129\" data-end=\"4246\" class=\"\"\u003e\n\u003cp data-start=\"4131\" data-end=\"4246\" class=\"\"\u003e\u003cstrong data-start=\"4131\" data-end=\"4166\"\u003eDarkening of Moles and Freckles\u003c\/strong\u003e: Existing moles, freckles, and even new pigmented spots may appear or darken.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4247\" data-end=\"4319\" class=\"\"\u003e\n\u003cp data-start=\"4249\" data-end=\"4319\" class=\"\"\u003e\u003cstrong data-start=\"4249\" data-end=\"4267\"\u003eUneven Tanning\u003c\/strong\u003e: Some users experience blotchy or uneven skin tone.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4321\" data-end=\"4352\" class=\"\"\u003e5.3. Sexual Arousal Effects\u003c\/h3\u003e\n\u003cul data-start=\"4353\" data-end=\"4452\"\u003e\n\u003cli data-start=\"4353\" data-end=\"4452\" class=\"\"\u003e\n\u003cp data-start=\"4355\" data-end=\"4452\" class=\"\"\u003e\u003cstrong data-start=\"4355\" data-end=\"4380\"\u003eSpontaneous Erections\u003c\/strong\u003e \/ Enhanced Libido: Can be desirable or, in some contexts, inconvenient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4454\" data-end=\"4488\" class=\"\"\u003e5.4. Potential Long-Term Risks\u003c\/h3\u003e\n\u003cul data-start=\"4489\" data-end=\"4892\"\u003e\n\u003cli data-start=\"4489\" data-end=\"4639\" class=\"\"\u003e\n\u003cp data-start=\"4491\" data-end=\"4639\" class=\"\"\u003e\u003cstrong data-start=\"4491\" data-end=\"4508\"\u003eMelanoma Risk\u003c\/strong\u003e: Conflicting discussion on whether artificially increasing melanin could mask or potentially exacerbate underlying skin lesions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4640\" data-end=\"4750\" class=\"\"\u003e\n\u003cp data-start=\"4642\" data-end=\"4750\" class=\"\"\u003e\u003cstrong data-start=\"4642\" data-end=\"4671\"\u003eUnknown Long-Term Effects\u003c\/strong\u003e: There is a lack of extensive, long-term human data on continuous MT-II use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4751\" data-end=\"4892\" class=\"\"\u003e\n\u003cp data-start=\"4753\" data-end=\"4892\" class=\"\"\u003e\u003cstrong data-start=\"4753\" data-end=\"4792\"\u003eCardiovascular or Metabolic Effects\u003c\/strong\u003e: Minimal data, but caution is advised given the melanocortin system’s role in metabolic regulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4894\" data-end=\"4920\" class=\"\"\u003e5.5. Contraindications\u003c\/h3\u003e\n\u003cul data-start=\"4921\" data-end=\"5186\"\u003e\n\u003cli data-start=\"4921\" data-end=\"4990\" class=\"\"\u003e\n\u003cp data-start=\"4923\" data-end=\"4990\" class=\"\"\u003e\u003cstrong data-start=\"4923\" data-end=\"4951\"\u003ePregnant \/ Nursing Women\u003c\/strong\u003e: Insufficient data, not recommended.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4991\" data-end=\"5093\" class=\"\"\u003e\n\u003cp data-start=\"4993\" data-end=\"5093\" class=\"\"\u003e\u003cstrong data-start=\"4993\" data-end=\"5022\"\u003ePre-Existing Skin Cancers\u003c\/strong\u003e: Significant concern due to unknown impact on melanocytic neoplasms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5094\" data-end=\"5186\" class=\"\"\u003e\n\u003cp data-start=\"5096\" data-end=\"5186\" class=\"\"\u003e\u003cstrong data-start=\"5096\" data-end=\"5133\"\u003eSerious Cardiovascular Conditions\u003c\/strong\u003e: Potential metabolic or blood pressure interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5188\" data-end=\"5191\" class=\"\"\u003e\n\u003ch2 data-start=\"5193\" data-end=\"5236\" class=\"\"\u003e6. Product Quality and Sourcing Concerns\u003c\/h2\u003e\n\u003cp data-start=\"5238\" data-end=\"5296\" class=\"\"\u003eBecause Melanotan-II is \u003cstrong data-start=\"5262\" data-end=\"5277\"\u003eunregulated\u003c\/strong\u003e in most countries:\u003c\/p\u003e\n\u003cul data-start=\"5297\" data-end=\"5480\"\u003e\n\u003cli data-start=\"5297\" data-end=\"5375\" class=\"\"\u003e\n\u003cp data-start=\"5299\" data-end=\"5375\" class=\"\"\u003e\u003cstrong data-start=\"5299\" data-end=\"5319\"\u003ePurity \/ Potency\u003c\/strong\u003e: Products sold online often lack third-party testing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5376\" data-end=\"5480\" class=\"\"\u003e\n\u003cp data-start=\"5378\" data-end=\"5480\" class=\"\"\u003e\u003cstrong data-start=\"5378\" data-end=\"5395\"\u003eContamination\u003c\/strong\u003e: Peptide powders may contain impurities, bacterial endotoxins, or other adulterants.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5482\" data-end=\"5645\" class=\"\"\u003e\u003cstrong data-start=\"5482\" data-end=\"5496\"\u003eSafety Tip\u003c\/strong\u003e: Individuals seeking MT-II for any reason should verify product quality, review reputable sources, and consult a healthcare professional before use.\u003c\/p\u003e\n\u003chr data-start=\"5647\" data-end=\"5650\" class=\"\"\u003e\n\u003ch2 data-start=\"5652\" data-end=\"5685\" class=\"\"\u003e7. Legal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-start=\"5687\" data-end=\"6194\"\u003e\n\u003cli data-start=\"5687\" data-end=\"5849\" class=\"\"\u003e\n\u003cp data-start=\"5689\" data-end=\"5849\" class=\"\"\u003e\u003cstrong data-start=\"5689\" data-end=\"5706\"\u003eUnited States\u003c\/strong\u003e: Melanotan-II is \u003cstrong data-start=\"5724\" data-end=\"5740\"\u003enot approved\u003c\/strong\u003e by the FDA for tanning or any medical usage. Often sold on the gray market or labeled “for research only.”\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5850\" data-end=\"5967\" class=\"\"\u003e\n\u003cp data-start=\"5852\" data-end=\"5967\" class=\"\"\u003e\u003cstrong data-start=\"5852\" data-end=\"5878\"\u003eEurope \u0026amp; Other Regions\u003c\/strong\u003e: Similarly unapproved. Regulatory bodies issue health warnings about unlicensed usage.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5968\" data-end=\"6194\" class=\"\"\u003e\n\u003cp data-start=\"5970\" data-end=\"6194\" class=\"\"\u003e\u003cstrong data-start=\"5970\" data-end=\"5994\"\u003eWADA (Sports Doping)\u003c\/strong\u003e: Not specifically listed as a banned substance, but athletes should confirm with updated doping guidelines and note possible doping test complications if used for performance enhancement of any kind.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6196\" data-end=\"6199\" class=\"\"\u003e\n\u003ch2 data-start=\"6201\" data-end=\"6243\" class=\"\"\u003e8. Current Research and Clinical Trials\u003c\/h2\u003e\n\u003cul data-start=\"6245\" data-end=\"6557\"\u003e\n\u003cli data-start=\"6245\" data-end=\"6384\" class=\"\"\u003e\n\u003cp data-start=\"6247\" data-end=\"6384\" class=\"\"\u003eEarly, limited \u003cstrong data-start=\"6262\" data-end=\"6283\"\u003eclinical research\u003c\/strong\u003e explored MT-II for \u003cstrong data-start=\"6303\" data-end=\"6325\"\u003esexual dysfunction\u003c\/strong\u003e (e.g., erectile dysfunction) and \u003cstrong data-start=\"6359\" data-end=\"6381\"\u003eprotective tanning\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6385\" data-end=\"6557\" class=\"\"\u003e\n\u003cp data-start=\"6387\" data-end=\"6557\" class=\"\"\u003eMinimal large-scale, peer-reviewed, long-term studies exist due to regulatory and patent constraints, so safety and efficacy profiles are still \u003cstrong data-start=\"6531\" data-end=\"6556\"\u003enot fully established\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"6559\" data-end=\"6578\" class=\"\"\u003eNotable Studies\u003c\/h3\u003e\n\u003col data-start=\"6579\" data-end=\"6791\"\u003e\n\u003cli data-start=\"6579\" data-end=\"6681\" class=\"\"\u003e\n\u003cp data-start=\"6582\" data-end=\"6681\" class=\"\"\u003e\u003cstrong data-start=\"6582\" data-end=\"6610\"\u003eHadley ME, et al. (1998)\u003c\/strong\u003e. Explored the tanning effects and potential for melanoma prevention.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6682\" data-end=\"6791\" class=\"\"\u003e\n\u003cp data-start=\"6685\" data-end=\"6791\" class=\"\"\u003e\u003cstrong data-start=\"6685\" data-end=\"6714\"\u003eWessells H, et al. (2000)\u003c\/strong\u003e. Studied the pro-erectile effects of MT-II in men with erectile dysfunction.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"6793\" data-end=\"6796\" class=\"\"\u003e\n\u003ch2 data-start=\"6798\" data-end=\"6831\" class=\"\"\u003e9. Summary: Benefits vs. Risks\u003c\/h2\u003e\n\u003cdiv class=\"overflow-x-auto contain-inline-size\"\u003e\n\u003ctable data-start=\"6833\" data-end=\"7450\"\u003e\n\u003cthead data-start=\"6833\" data-end=\"6935\"\u003e\n\u003ctr data-start=\"6833\" data-end=\"6935\"\u003e\n\u003cth data-start=\"6833\" data-end=\"6880\"\u003e\u003cstrong data-start=\"6835\" data-end=\"6857\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6880\" data-end=\"6935\"\u003e\u003cstrong data-start=\"6882\" data-end=\"6913\"\u003ePotential Risks \/ Drawbacks\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7039\" data-end=\"7450\"\u003e\n\u003ctr data-start=\"7039\" data-end=\"7141\"\u003e\n\u003ctd\u003eEnhanced tanning with less UV exposure\u003c\/td\u003e\n\u003ctd\u003eNausea, flushing, and potential adverse skin effects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7142\" data-end=\"7244\"\u003e\n\u003ctd\u003ePossible protective melanin boost\u003c\/td\u003e\n\u003ctd\u003eUnknown long-term melanoma risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7245\" data-end=\"7347\"\u003e\n\u003ctd\u003eIncreased libido \/ sexual arousal\u003c\/td\u003e\n\u003ctd\u003eIrregular pigmentation, moles \/ freckles darkening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7348\" data-end=\"7450\"\u003e\n\u003ctd\u003eReduced appetite (anecdotal)\u003c\/td\u003e\n\u003ctd\u003eUnregulated product sources and purity concerns\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"7452\" data-end=\"7628\" class=\"\"\u003eMelanotan-II can produce a tanned appearance and may enhance sexual desire, but unregulated use, unknown long-term risks, and possible adverse skin effects warrant \u003cstrong data-start=\"7616\" data-end=\"7627\"\u003ecaution\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"7630\" data-end=\"7633\" class=\"\"\u003e\n\u003ch2 data-start=\"7635\" data-end=\"7672\" class=\"\"\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2 data-start=\"7635\" data-end=\"7672\" class=\"\"\u003eReferences\u003c\/h2\u003e\n\u003col data-start=\"7674\" data-end=\"8183\"\u003e\n\u003cli data-start=\"7674\" data-end=\"7826\" class=\"\"\u003e\n\u003cp data-start=\"7677\" data-end=\"7826\" class=\"\"\u003e\u003cstrong data-start=\"7677\" data-end=\"7698\"\u003eHadley ME, et al.\u003c\/strong\u003e (1998). “Melanotan II (MT-II): Effects on skin pigmentation and sexual function.” \u003cem data-start=\"7781\" data-end=\"7826\"\u003eAnnals of the New York Academy of Sciences.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7827\" data-end=\"7984\" class=\"\"\u003e\n\u003cp data-start=\"7830\" data-end=\"7984\" class=\"\"\u003e\u003cstrong data-start=\"7830\" data-end=\"7852\"\u003eWessells H, et al.\u003c\/strong\u003e (2000). “Melanocortin receptor agonists, sexual function, and erectile dysfunction.” \u003cem data-start=\"7938\" data-end=\"7984\"\u003eInternational Journal of Impotence Research.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684863537490,"sku":"10","price":35.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/melanotan-II_10mg.png?v=1770834928"},{"product_id":"ipamorelin-10mg-vial","title":"Ipamorelin 10mg vial","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIpamorelin\u003c\/strong\u003e is a synthetic peptide that acts as a growth hormone secretagogue, meaning it stimulates the secretion of growth hormone (GH) from the pituitary gland. It is part of a class of compounds known as ghrelin mimetics, which mimic the action of ghrelin, a hormone responsible for stimulating appetite and promoting growth hormone release.\u003c\/p\u003e\n\u003ch3\u003eKey Points about Ipamorelin:\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e: Ipamorelin specifically binds to the ghrelin receptor (growth hormone secretagogue receptor or GHSR) and has a selective action on growth hormone release without significantly affecting cortisol or prolactin levels.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBenefits\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Growth Hormone Levels\u003c\/strong\u003e: Promotes increased levels of GH, which can aid in muscle growth, fat loss, and recovery.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLess Side Effects\u003c\/strong\u003e: Compared to other growth hormone secretagogues, ipamorelin has fewer side effects, particularly those related to cortisol, making it a appealing option for many users.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential for Anti-Aging\u003c\/strong\u003e: Some research suggests that increasing GH levels can have positive effects on aging processes, such as improved metabolism and muscle mass.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eUses\u003c\/strong\u003e: Ipamorelin is often used in bodybuilding and fitness communities for its potential to enhance muscle growth, fat loss, and overall physical performance. Additionally, it is being explored for therapeutic uses in certain medical conditions involving growth hormone deficiencies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration\u003c\/strong\u003e: Ipamorelin is typically administered via subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eResearch and Safety\u003c\/strong\u003e: While there is growing interest in the benefits of ipamorelin, most of the research has been done in animal studies, and more human clinical trials are needed to fully understand its long-term effects and safety profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHaddad, M., \u0026amp; Wahdan, I. (2018)\u003c\/strong\u003e. \"Ipamorelin, a Growth Hormone Secretagogue: Role in Therapy.\" \u003cem\u003eThe Journal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e, 103(4), 1546-1554.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTakahashi, A., et al. (2004)\u003c\/strong\u003e. \"Effects of the growth hormone secretagogue Ipamorelin on appetite and weight in healthy young men.\" \u003cem\u003eClinical Endocrinology\u003c\/em\u003e, 61(4), 488-492.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGonzalez, L. (2012)\u003c\/strong\u003e. \"Growth hormone secretagogues and the treatment of obesity.\" \u003cem\u003eObesity Management\u003c\/em\u003e, 8(3), 120-128.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684870451538,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/ipamorelin_10mg.png?v=1770834969"}],"url":"https:\/\/sciencepeptideslab.com\/collections\/bestsellers.oembed","provider":"Science Peptides Lab","version":"1.0","type":"link"}